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Background and purpose: With the advent of antiretroviral therapy, HIV-infected individuals now live longer 
and are at increased risk of chronic kidney disease (CKD). Also, recent studies indicate a genetic predisposition 
to CKD in the African HIV population. This work investigated the prevalence of CKD (and its correlates) in the 
global and local HIV population and proceeded to investigate the diagnostic utility of urinary transforming 
growth factor-beta-1 (TGF-β1) for CKD in the HIV population and determine the association between 
polymorphisms of TGF-β1 gene and prevalent CKD. 
Methods: A meta-analysis was performed to document the prevalence of CKD in the global HIV population. 
From the local HIV population in Nigeria, the prevalence of CKD and traditional risk factors for cardiovascular 
disease was determined. Using ELISA, TGF-β1 levels was assayed in the urine samples of HIV patients with or 
without CKD to investigate the ability of urinary TGF-β1 to diagnose early CKD. SNP genotyping of rs1800469, 
rs1800470, rs1800471, rs121918282 in TGF-β1, rs60910145 (APOL1), rs73885319 (APOL1), rs71785313 
(APOL1) and rs743811 (HMOX1) was performed using predesigned TaqMan genotyping assays.  
Results: Using meta-analytic methods, the global pooled CKD prevalence was 6.4% (95%CI 5.2–7.7%) with 
MDRD, and 4.8% (2.9–7.1%) with CKD-EPI. Among the WHO regions, Africa had the highest MDRD-based 
prevalence, 7.9% (5.2-11.1%) with the West African subregion carrying the heaviest burden, 14.6% (9.9-
20.0%). Among the local HIV population, using the CKD-EPI equation, the prevalence of CKD was 13.4% (11.6-
15.4%). Hypertension prevalence was 26.7% (25.5-28.0%); diabetes 5.6% (4.5-6.7%); obesity 8.3% (7.6-9.1%) 
and dyslipidaemia 29.1% (26.1-32.1%). HIV-infected individuals with CKD had significantly higher levels of 
urinary TGF-β1-creatinine ratio (uTGFβ1Cr) after controlling for potential confounding factors in regression 
models. However, within the CKD-HIV group, uTGFβ1Cr reduced as CKD stage worsened. The presence of 
APOL1 genetic risk independently increased the risk of CKD (OR 2.54, 95% CI 1.44-4.51) in the HIV population 
while the TGF-β1 SNP, rs1800470, appeared to have a protective effect (OR 0.44 (95% CI 0.20-0.97). There was 
no significant association between HMOX1 SNPs and CKD occurrence. 
Conclusion: There is a high prevalence of CKD (and other cardiovascular risk factors) in the adult HIV-
population. Urinary TGF-β1 may be useful in the non-invasive detection of early CKD in the HIV population. 
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CHAPTER ONE: INTRODUCTION 
About thirty years ago, it was first noticed that the Human Immunodeficiency Virus (HIV) may be a risk factor 
for Chronic Kidney Disease (CKD) (1). At that time, the focal and segmental glomerular lesions seen in HIV-
positive patients was not only associated with massive proteinuria but had a rapid decline to End Stage Renal 
Disease (ESRD) and high mortality rates (1, 2). Within a few years, it was agreed that an entity with distinct 
sociodemographic, clinical and histologic features was a predominant cause of CKD in HIV patients. This entity, 
called HIV–associated Nephropathy (HIVAN), was noted to be the predominant cause of CKD in HIV patients of 
Black African origin; regarded as an AIDS–defining illness and had strong evidence of intra-renal HIV gene 
expression (3-5).  
With the advent of Antiretroviral Therapy (ART), individuals with HIV disease are living longer (6). We now see 
a wide spectrum of renal diseases in HIV patients ranging from asymptomatic changes in renal function like 
proteinuria (7, 8), electrolyte losses (9) and acute kidney injury (AKI) (10) occurring as a result of diarrheal 
diseases prevalent among HIV patients to CKD. The renal histologic types in CKD patients with HIV disease are 
also quite varied. HIVAN, a form of focal segmental glomerulosclerosis (FSGS) with significant tubulointerstitial 
pathology is the most common histologic type encountered in HIV patients, especially in Black populations 
(11). There is also a variety of immune complex glomerulonephritides collectively known as HIV – immune 
complex kidney disease (HIVICK) which could account for as much as 31% of glomerular lesions in HIV patients 
with CKD (11, 12). HIV disease does not preclude the presence of other aetiologies of CKD. Non-collapsing 
FSGS, interstitial nephritis and diabetic nephropathy (and other vascular and metabolic effects on the kidneys) 
have been documented in HIV patients (13-15). Arterionephrosclerosis has been  documented to be the most 
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common histologic diagnosis in HIV patients with no clinical indication for renal biopsy in the post-ART era 
(16). Also, the continued use of tenofovir and ritonavir-based ART has been shown to increase risk of 
development of CKD (17). 
Among incident ESRD patients, HIV has been implicated as the main etiologic factor in 1% (USA); 0.36% - 
0.67% (France)(18, 19); 0.54% - 1.15% (Spain) (20, 21)  6.6% (Cameroon) (22); and 28.5% (South Africa)(23).  
Depending on the definition of CKD in different HIV populations, the prevalence of CKD has been varied. In the 
United States, the prevalence in a cohort of HIV–positive women at baseline (before commencing ART) was 
7.2% and this increased to 14% within 21 months of commencing treatment (24). In a predominant male HIV 
population in the United States, the prevalence was put at 8.5% (25) but could be as high as 15.5% (26). In 
Brazil, analysis of about 1,900 adult HIV patients revealed a CKD prevalence of 13.3% (27). It also appears 
duration on treatment and type of ART influences CKD prevalence. As much as 3.3% of HIV patients with 
normal estimated glomerular filtration rate (eGFR) may develop CKD in a median follow up period of 3.7 years 
(28). About 5% of HIV infected adults in China had eGFR< 60ml/min/1.73m2(29). 
The prevalence of CKD in HIV populations across Africa is not well documented despite having the highest 
worldwide burden of HIV. A study in South Africa recorded a prevalence of 7.3% (7) which is not too different 
from data in other parts of the world. A Kenyan study had a prevalence of 11.5% (30) while a relatively small 
study from Nigeria had a high prevalence of 24% (31). Another Nigerian study had 38% of their HIV cohort 
having either elevated serum creatinine or persistent proteinuria but was only able to biopsy ten individuals 
because of the lack of histopathological facilities (32, 33). Other Nigerian studies (31, 34, 35) have 
documented a prevalence of CKD of 38% - 53.5% depending on the definition of CKD but none had a sample 
size exceeding 400 for a condition such as HIV that is highly prevalent. Considering that HIV patients are living 
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longer, and that kidney disease is becoming a major cause of morbidity and mortality in this patient 
population it is important to have reliable data on the burden of CKD among HIV patients. The effect of rising 
CKD prevalence in the HIV population may become a difficult burden for an already fragile health system in 
most Sub-Saharan African countries. 
1.1 RATIONALE FOR THIS STUDY  
The burden of CKD continues to increase in developing countries through increasing non – communicable 
diseases (NCDs) and the huge burden of HIV.  With the rising economic challenges and poverty in low- and 
middle-income countries (LMICs) and with poor health care facilities, the problems associated with the 
treatment of CKD/ESRD will be dire. Understanding the burden of CKD as well as risk factors for CKD in the 
large HIV population is an initial first step towards implementing health care strategies to combat these 
conditions. Moreover, the role of biomarkers (such as TGF-β) and other genetic factors (besides APOL1) have 
not been previously studied in Sub-Saharan African population even though there is evidence that they may 
be useful markers and may play a role in progression of CKD, respectively. The present study is therefore 
important as it will provide critical answers to questions around epidemiology and pathogenesis of CKD in the 
HIV population in Nigeria and beyond.   
   
1.2 PATHOGENESIS OF HIV – RELATED NEPHROPATHIES 
HIVAN, the commonest HIV – related nephropathy in Blacks, is believed to require the expression of HIV- 1 
gene in the kidney for its pathogenesis (36) and HIV-1 genetic material has been detected in renal epithelial 
cells (RECs) even  when undetectable levels of viral RNA have been achieved in plasma (37). The human RECs, 
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renal Tubular epithelial cells (RTECs) and renovascular cells lack CD4 receptors and the co-receptors CXCR4 
and CCR5 (36, 38, 39), therefore the mode of entry of HIV into the RECs and RTECs remains unclear. Some 
have suggested the existence of kidney-tropic strains of HIV following observation of certain strains of HIV 
which are capable of infecting epithelial cells independent of the CD4 pathway (39). It is possible however to 
have a direct transfer of viral RNA from infected CD4+ T-cells to RTECs when there is stable cell-cell adhesion 
in the presence of heparin sulfate proteoglycans (40). In HIVAN, infection of the podocytes results in increased 
proliferation, apoptosis and dedifferentiation of the podocytes. There is also upregulation of genes encoding 
for inflammatory proteins leading to initiation of a cascade of inflammatory events leading to tubulointerstitial 
fibrosis (41).  
HIV – immune complex kidney disease (HIVICK), on the other hand, is less common than HIVAN. While it has 
been established that viral expression alone in the RECs and RTECs are able to initiate the lesions seen in 
HIVAN, this cannot be said to be true with HIVICK (42). In HIVICK, active viral replication and immune response 
to viral proteins herald the onset of the renal lesions. HIVICK is typically associated with co-infection with 
Hepatitis C virus and is characterized by immune complex (Complement, HIV-1 antigens and reactive 
antibodies) deposition (43).  The commonly implicated viral proteins, Nef, Vpr and Tat have been shown to 
initiate complex inflammatory response to their presence and Vpr alone has been shown to cause kidney 
inflammation (43). Clinically, HIVICK is also predominantly found in Blacks, have lower HIV RNA viral loads and 
higher CD4 counts than found in HIVAN and are more likely to have concurrent diabetes mellitus and 
hypertension than HIVAN patients (44). They are also less likely to progress to ESRD than HIVAN patients. 
HIV-associated thrombotic microangiopathy (HIVTMA) is the most uncommon of the HIV related kidney 
diseases encountered in about 0.3% (45) of HIV patients having an incidence of 0.079 per 100 person–years of 
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follow up. It is said to be associated with lower CD4 counts, higher viral loads and co-infection with 
Mycobacterium Avium-intracellulare complex (45). The characteristic histologic feature of HIVTMA is a dearth 
of inflammatory cells with increased evidence of apoptosis of microvascular endothelial cells (46). Clinically, 
patients may present with low grade thrombocytopenia and mild renal insufficiency or as severe renal failure 
needing renal replacement therapy associated with neurologic deficits. Therapeutic plasma exchange appears 
to give some benefit for patients that develop HIVTMA (46). 
1.3 KIDNEY DISEASE FOLLOWING TREATMENT OF HIV 
The drug treatment of HIV/AIDS is also implicated in the development of both acute and chronic kidney 
disease. Acute Kidney Injury (AKI) could occur in as much as 5.7-10% of patients initiated on ART and is usually 
caused by both traditional factors known to cause AKI and the use of Cotrimoxazole (47-49). A number of 
these patients with AKI do progress to CKD on follow-up.  Tenofovir disoproxil fumarate (TDF) is associated 
with severe AKI sometimes but more commonly its effect may be completely asymptomatic (48). The 
diagnosis of ART–induced CKD should be a diagnosis of exclusion, seeing the spectrum of conditions in HIV 
patients that can lead to CKD. Though the incidence of CKD attributable to ART use is relatively low, 2.7 to 7% 
(50), the numbers of those affected may place an increased demand for care in large HIV care programs in 
Sub-Saharan Africa. The commonly implicated antiretroviral medications causing CKD include TDF (51, 52), 
indinavir (53) and atazanavir (54). The risk of CKD while on ART increases in the presence of traditional risk 
factors for CKD e.g. hypertension, diabetes mellitus and concomitant use of nephrotoxic medications. Other 
identified risk factors include nadir CD4 count of less than 200 cells/mm3, opportunistic infection and longer 
ART use (50). The combination of Ritonavir and TDF has been found to increase the risk of renal toxicity (55) 
and the Fanconi syndrome occurring 0.3 to 2% of patients on ART are mostly attributable to TDF (56). Acute 
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interstitial nephritis is known to occur in patients taking abacavir, indinavir, atazanavir and ritonavir (57). 
These observations now indicate the need for more collaboration between Primary HIV–care providers and 
Nephrologists for the purpose of early detection and treatment of renal toxicities in these patients. 
Assessment of renal function before beginning ART should be made mandatory in all HIV care facilities and 
protocol for regular renal function check instituted. Dose adjustment should be employed in patients where 
the offending drug cannot be substituted because of the overarching benefits of the medication. More 
recently, the development of Tenofovir Alafenamide (TAF) that has shown less toxicity and reduction in eGFR 
compared to TDF has brought hope for patients that really need Tenofovir (58). Long term data on TAF 
regarding renal safety is still being awaited.   
1.4 TRADITIONAL RISK FACTORS FOR CKD IN THE HIV POPULATION 
Traditional risk factors for CKD like hypertension, Diabetes Mellitus (DM), Obesity and Dyslipidemia also 
contribute to renal function decline in HIV patients. Whether there is a difference in prevalence of these 
metabolic syndrome factors in the HIV population compared to the general population has been investigated 
in different climes. A DM prevalence of 5.6% found in Guinea Bissau among ARV–naïve HIV patients was noted 
to be higher than the general population and occurring in younger individuals (59). Among Ethiopians with 
HIV, a very high prevalence of DM, 31%, has been reported compared to 8% in non-HIV infected Ethiopians 
despite relatively low BMI (60). This finding did not hold true in Puerto Rico where the 13.7% recorded among 
HIV patients was not significantly different from the 12.8% in the general population (61). The increased 
prevalence/incidence of DM in the HIV population may partly be due to dysglycemia caused by use of non-
nucleoside reverse transcriptase inhibitors that constitute part of first line therapy for HIV (62). ART may be 
implicated in the higher prevalence of cardiovascular risk factors such as hypertension and dyslipidemia. The 
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prevalence of hypercholesterolaemia was 8 times higher in the group of patients on ART compared to the 
ART–naïve group in a Cameroonian study (63). Studies have found hypertension prevalence (26.5%) twice 
higher in the ART group compared to the ART–naïve group (63, 64) and obesity prevalence of 11% in ART 
patients compared to 2% in the ART–naïve patients (65). More traditional markers of cardiovascular risk like 
insulin resistance has been found to be higher in HIV patients than non-HIV controls (66).  
1.5 RISK OF CKD OCCURRENCE IN HIV PATIENTS 
Seeing that HIV cohorts round the world are living longer and therefore accumulating many other factors that 
could increase the risk of CKD (including age, hypertension, Diabetes Mellitus, dyslipidemia and use of ART), it 
would be important to predict the risk of development of CKD in this “at-risk” population. This led to the 
development of the D:A:D risk score for CKD progression in HIV patients (67). Unfortunately, the population 
used for the development of this score had only 7.2% of the study population being Black and the population 
used for validation was also predominantly Caucasian making it difficult to employ this risk score in Black HIV 
patients. Validation of this risk score in a large Black HIV positive population would be of immense help to HIV 
clinicians in predicting risk of CKD progression therefore creating an opportunity to influence modifiable risk 
factors for high risk HIV patients. Seeing that the HIV population is a high-risk group for the development of 
CKD, it is therefore imperative to clearly define CKD in this group. 
1.6 CKD DEFINITION IN THE HIV POPULATION 
Chronic Kidney Disease, on the most part, is defined using glomerular filtration rate (GFR). GFR can be 
measured directly or estimated using equations based on serum creatinine or Cystatin C levels. The accuracy 
of creatinine based estimated GFR (eGFR) in HIV populations has been a source of debate among researchers. 
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The more clinically established creatinine-based equations – the Cockcroft–Gault (CG); Modification of Diet in 
Renal Disease (MDRD) and CKD-EPI equations were derived from Western populations and have not been 
appropriately validated in Black Africans, much less in HIV–infected Black Africans. An attempt to validate 
these creatinine-based equations in Black South Africans suggested a removal of the race factor in the 
equations (68). This too will require validation with a larger population of Black individuals and different Black 
races. The lack of reliability of serum creatinine measurements may also affect eGFR calculated from 
creatinine–based equations. In HIV patients, there is a tendency of muscle wasting, which may lead to 
spuriously low serum creatinine levels and therefore overestimation of GFR if creatinine–based equations are 
employed.  Conversely, the weight gain that occurs following ART therapy may lead to serum creatinine 
increases which may falsely suggest GFR reductions. Some have suggested that Cystatin–C based equations be 
employed but this too requires validation and is known to be affected by ongoing inflammation and HIV 
replication (69). The use of proteinuria (or persistent proteinuria) in HIV patients may also be problematic 
because of the increased incidence of urinary tract infection (UTI), including recurrent UTI in this patient 
population. While this debate about GFR estimation in HIV patients continues, most researchers and clinicians 
will continue to use the creatinine–based equations till studies show clear evidence for the use of another 
formula. Equations combining Serum creatinine and Serum Cystatin C have been shown to improve accuracy 
of CKD diagnosis better than serum creatinine or serum Cystatin C alone (70).The concern about serum 
creatinine-based formulae lies majorly in the fact that it may be too late to reverse changes in the kidneys by 
the time creatinine begins to rise in blood therefore missing the golden time for intervention. This has led to a 
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1.7 URINARY BIOMARKERS OF CKD IN HIV PATIENTS 
Research on urinary biomarkers in HIV has aimed at finding molecules that their urinary levels will help in the 
diagnosis of early AKI before the onset of serum creatinine increase; determine ongoing renal tubular damage 
of tubulotoxic ART agents and associated antibiotics or predict progression to CKD. One of such markers is α1–
microglobulin (a marker of proximal tubular dysfunction) which has been found to predict GFR decline over a 
10-year period in HIV–infected women (71) and may be better than β2–microglobulin (β2m), N- acetyl- β-d-
glucosaminidase (NAG) and albumin/creatinine ratio in detecting TDF-induced tubular dysfunction in HIV men 
(72).  Other biomarkers associated with GFR decline and/or all-cause mortality in HIV cohorts include Kidney 
injury molecule–1 (KIM-1), Neutrophil gelatinase–associated lipocalin (NGAL), Liver fatty acid binding protein 
(L-FABP) and Interleukin 18 (IL-18) (73, 74). These molecules have been extensively investigated in AKI and 
have shown promise for CKD prediction. However, cycle arrest urinary biomarkers like Tissue inhibitor of 
metalloproteinase 2 (TIMP-2) and Insulin-like growth factor–binding protein 7 (IGFBP7) appear to have 
performed better than KIM-1 and NGAL in predicting the development of moderate to severe AKI (70). Maybe 
a panel of these urinary biomarkers may be more helpful in predicting CKD progression than single biomarkers 
(73, 75) but this would significantly increase cost of care and may not be clinically practicable in resource-poor 
settings of Sub-Saharan Africa where the burden of HIV disease is highest. Many of these biomarkers are 
increased in urine when there is injury to renal tubular or epithelial cells but other biomarkers (such as 
transforming growth factor–beta [TGF-β]) may measure the degree of fibrosis occurring in the renal 
interstitium and could therefore perform better for predicting chronic damage to the kidneys.  
TGF-β is a multifunctional peptide that has three isoforms - TGF-β1, TGF-β2, TGF-β3 and is part of the TGF-β 
superfamily of cytokines which consists of the isoforms of TGF-β, Bone Morphogenic Protein (BMP), Inhibin 
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and Activin (76). TGF-β1, the first discovered in 1983, the most abundant and probably the most effective (77), 
is a 25KDa peptide with 112 amino acid residues (78) derived from a larger protein precursor that has 390 
amino acid residues (Pre-pro TGF-β). Pre-pro- TGF-β has a hydrophobic 29 amino acid signal sequence which is 
cleaved to obtain Pro- TGF-β (latent form of TGF-β1). This latent form of TGF-β1 is made up of TGF-β1 and 
Latency–associated peptide (LAP) which binds to LTBP (Latent TGF-β binding protein) in the target tissues (10). 
The carboxyl terminal 112 amino acid sequence that makes up TGF-β is cleaved from Pro- TGF-β at a dibasic 
cleavage site to release the active TGF-β1 when exposed to a variety of stimuli (10). TGF-β is ubiquitous and 
produced by virtually every cell in the body. All TGF-β share the same receptor but with differing affinity (79).  
TGF-β1 binds to a transmembrane receptor, TGF-β receptor II but exerts its effects only in the presence of 
TGF-β receptor I. It has been shown that both receptors must be present for its intracellular effect to be 
initiated (80). The actions of TGF-β1 hereafter, acting in a paracrine and autocrine way, is pleiotropic.  
1.8 Pathogenesis of renal fibrosis by TGF-B  
The discussion following will focus on the profibrotic and antifibrotic pathways with which TGF-β1 exerts its 








Figure 1: Meng XM et al. Nat Rev 2016 doi:10.1038/nrneph.2016.48 (Reproduced with permission) 
LTBP – Latent TGF-β Binding Protein; LAP - Latency–associated peptide; TGF-β1 – Transforming Growth factor – beta 1; TGFR1 – Transforming 
Growth factor Receptor 1; TGFR2 – Transforming Growth factor Receptor 2; Smad - Mothers Against Decapentaplegic, Drosophila  
 
Activated TGFR2 then activates TGFR1 which phosphorylates Smad2 and Smad3. These Smad proteins 
complex with Smad4 and exerts its influence in the nucleus by binding to gene promoters to induce 
production of profibrotic molecules which induce matrix deposition. Smad3 also causes transcription of 
profibrotic microRNA (miRNA) and long noncoding RNA (lncRNA and inhibits transcription of antifibrotic 
miRNAs (10).  
 
 




Figure 2: Meng XM, et al. Front Physiol. 2015; 6: 82. TGF-b in Renal fibrosis (Reproduced with permission) 
This pathway is so important in the pathogenesis of renal fibrosis that researchers now believe that targeting 
the TGF-β/Smad 3 system may be one avenue of slowing down CKD progression (81).  
1.9 URINARY TGF-β1 AS A POSSIBLE BIOMARKER FOR CKD IN HIV PATIENTS  
Following from the above, studies have indicated increased urinary excretion of TGF-β in a variety of renal 
glomerular and lesions – Diabetic nephropathy (82, 83), Lupus Nephritis, IgA nephropathy, Rapidly progressive 
glomerulonephritis (RPGN), forms of Chronic glomerulonephritis and interstitial nephritis (84, 85). Some have 
been able to show correlation between serum creatinine and urinary TGF-β levels but correlation with degree 
of interstitial fibrosis has not been consistent.  
More indirect evidence about the role of TGF-β in CKD progression abound. Individuals with IgA nephropathy 
treated with prednisolone have been observed to have reduced urinary TGF-β1 levels compared to pre-
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treatment levels (86, 87). IgA nephropathy patients treated with Losartan also had their urinary TGF-β levels 
significantly reduced (88). More recently, elevated urinary TGF-β levels have also been demonstrated in HIVAN 
patients (89).  An increased expression of TGF-β in Blacks compared to Caucasians has been well documented 
in end-stage renal disease and hypertensive patients (90-92). This increases our suspicion that TGF-β may be 
elevated in the urine of our Black patients with CKD and may play a central role in the increased burden of CKD 
in HIV positive Black patients. Therefore, accurate measurement of this cytokine in well collected urine 
samples may be useful in detecting early renal damage and predicting progression to CKD in HIV patients as it 
has been done in other glomerular and tubulointerstitial disease (93).   
1.10 TGF-Beta POLYMORPHISMS IN AFRICANS AND THEIR ROLE IN KIDNEY DISEASES 
Polymorphisms in the gene coding for TGF-β1 may also be associated with CKD. In an important study among 
Caucasians in the UK (94), single nucleotide polymorphisms (SNPs) in the TGFβ1 gene were  found to be 
associated with progression of chronic kidney disease. Indeed, the study showed significant differences 
in the allele frequencies of C-509T (p=0.02) and Leu10Pro (p=0.038). There was also significant 
association between CKD progression and homozygosity for Arg25. Other studies among Diabetic 
patients have found association of the TGF-β1 gene polymorphisms (T869C, 915G>C, -800G>A, codon 10, 
T29C) with the development and/or progression of CKD in Caucasian and Asian populations (95-99). There is a 
dearth of TGF-β1 genetic polymorphism studies in relation to CKD in Sub-Saharan Africa. 
1.11 APOL1 and HMOX1 GENE POLYMORPHISMS AND CHRONIC KIDNEY DISEASE PROGRESSION 
APOL1 kidney disease risk alleles (G1 and G2) are common throughout Sub-Saharan Africa especially West 
Africa and African Americans of West African descent (100). APOL1 mediated kidney disease tends to follow a 
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recessive mode of inheritance with those with 2 alleles having greater risk of progression to end–stage kidney 
disease (100). A spectrum of CKD aetiologies (including HIV) have been associated with APOL1 risk alleles. 
Indeed, the absence of these risk variants in some populations has been thought to be the reason for the low 
prevalence of HIVAN in Ethiopian communities (101). While this may be true, others have suggested that 
other genetic, viral and environmental factors should be sought as contributors to progression of CKD (102) 
among the HIV population as APOL1 alone does not completely explain CKD progression in this special 
population. Finding an association between these APOL1 risk variants and HIV–related kidney disease in 
Nigeria may be helpful in planning CKD prevention programs among HIV population in Nigeria and beyond.  
Moreover, HMOX1 forms the rate-limiting step in the catabolism of free heme (103), with two promoter 
polymorphisms, a GT-dinucleotide repeat (rs3074372) and a SNP (rs743811), associated with CKD (104, 105). 
Genetic variations in both APOL1 and HMOX1 have been associated with Sickle cell nephropathy among adult 
African Americans (104, 106, 107). In parts of Cameroon which has historical relationship with the part of Nigeria 
where this work was undertaken, borderline association has been found between HMOX1 and 
microalbuminuria (108). The study of associations between these genomic variants, in HMOX1 and the 
development of CKD has not yet been investigated in HIVAN.  
 
Gene-gene interactions associated with CKD 
It is believed that individuals with the APOL1 genetic risk who do not develop CKD either have some protective 
factor or have not been exposed to additional risk that acts as a ‘second hit’. These factors could either be 
genetic in nature or environmental.  
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Genetic factors documented to modify the risk of APOL1 for ESRD include SNPs in the podocin gene, NPHS2, 
which reduce the risk of ESRD in APOL1 associated nephropathy while the serologically defined colon cancer 
antigen 8 (SDCCAG8) increased the risk of ESRD in nondiabetic individuals (109, 110). However, no gene-gene 
interaction has ever been documented between APOL1 and TGF-β1 or HMOX1 in any population. Indeed, a 
recent genome-wide association study (111) failed to identify any gene-gene interaction with APOL1, rather 
environmental factors (like HIV disease) appear to be more important as a second hit, leading to progression of 
CKD to ESRD. 
Gene-environment interactions associated with CKD 
The relationship between APOL1 risk alleles and HIV is considered a classical example of gene-environment 
relationship leading to CKD. It has been shown that African Americans (112) and black South African individuals 
(113) with the APOL1 genetic risk and HIV infection have significantly increased risk of CKD and that the use of 
appropriate ARVs blunts this risk, to the extent that HIV-positive individuals with APOL1 genetic risk who have 
achieved viral replication control are unlikely to develop HIVAN. Other identified environmental factors that 
modify CKD risk in individuals with APOL1 genetic risk includes the JC polyomavirus infection which has been 
shown to reduce the risk of CKD in HIV-positive individuals with the APOL1 risk allele (114). There is no 
documented evidence of gene-environment interactions leading to CKD regarding TGF-β1 or HMOX1. 
1.12 Purpose of thesis: 
This work investigated the prevalence of CKD (and its correlates) in the global and local HIV population and 
proceeded to investigate the diagnostic utility of urinary transforming growth factor-beta-1 (TGF-β1) for CKD in 
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the HIV population and determine the association between polymorphisms of TGF-β1, APOL1 and HMOX1 genes 
and prevalent CKD. 
 
1.13 Research questions: 
The series of questions this thesis will answer using separate but related publications include:  
1. What is the prevalence of CKD in the global HIV population? Do regional and sub-regional differences 
occur in the prevalence of CKD among the HIV population in these regions? 
2. What is the prevalence of CKD in the local HIV population in Nigeria? 
3.  What is the prevalence of other CVD risk factors in the local HIV population? 
4. Is there a relationship between urinary TGF-beta levels and prevalent CKD in the adult HIV population? 
5. Is there an association between genetic polymorphisms of TGF-β1, APOL1 and HMOX1 and prevalent 
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CHAPTER TWO: OVERVIEW OF METHODS 
To meet the research objectives of this study, it has been divided into the following sub-studies which have 
been schematically summarized in Figure 3 below. 
 
Figure 3: Outlay of Planned activities 
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In presenting the overall study methodology, I have taken advantage of the sub-studies shown in Figure 3 
(above) to describe the methods used in each sub-study to achieve the aims of this study. Therefore, although 
the study location and patient population are the same, the methods used in each sub-study is separately 
presented in sections 2.1 (sub-study 1); 2.2 (sub-study 2); 2.3 (sub-study 3); 2.4 (sub-study 4) and 2.5 (sub-
study 5). 
THE STUDY POPULATION 
Uyo, the Capital City of Crude Oil rich Akwa Ibom State of Nigeria is located 5°2′N 7°55′E. Akwa Ibom is a 
rapidly growing state with its southern limits extending into the Atlantic Ocean of West Africa. The state has a 
population of 4.6 million according to latest United Nations estimates (115) with the predominant occupation 
being farming for those living in the hinterlands and fishing for those in communities near the Ocean and 
public service for individuals in the Urban areas. It has only one tertiary hospital, the University of Uyo 
Teaching Hospital, a 520 – bed hospital affiliated to the University of Uyo, Nigeria.  
STUDY LOCATION 
This study was undertaken at the HIV Clinic of the University of Uyo Teaching Hospital which started 
operations in 2006 and has registered a little over twelve thousand patients since inception. About four 
thousand patients are on ART while the loss to follow up rate has been computed to be 15 – 20% depending 
on duration since enrollment. At entry, after confirmation of patients’ HIV status, patients have their CD4 
count, viral load, Complete blood count, serum electrolytes, urea and creatinine, Liver function test done. 
Patients who meet criteria are commenced on ART after ensuring they have treatment partners who will help 
ensure adherence to therapy and clinic visits. Follow up visits are every 3 months; repeat CD4 count 6–
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monthly and viral load annually.  There has been an increase in the number of patients with kidney disease 
referred from this clinic to the renal clinic of the hospital in the last four years (116). 
 
2.1  SUB-STUDY 1: SYSTEMATIC REVIEW/META ANALYSIS OF PREVALENCE OF CKD IN THE GLOBAL ADULT 
HIV POPULATION 
A systematic review/meta-analysis was undertaken to determine the prevalence of CKD in other HIV 
population worldwide using eGFR of ≤ 60ml/min/1.73m2 as definition of CKD. 
SEARCH STRATEGY 
A comprehensive electronic search was done to identify all studies that are deemed relevant to this review, 
with no language restriction, regardless of publication status (published, unpublished, in press and in 
progress). We will search the  
1. PUBMED 1982 till date 
2. Web of Science 
3. EBSCO host 
4. Africa Journals online (AJOL) 
We also did a handsearch of the reference lists of identified articles and relevant review articles using search 
terms: HIV AND (“CKD” or Chronic Kidney failure or Chronic renal failure or chronic renal insufficiency or 
Chronic Kidney insufficiency) AND “Prevalence” OR “Incidence” OR “eGFR<60ml/min” OR “Proteinuria”. 
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ASSESSMENT OF METHODOLOGICAL QUALITY OF ARTICLES 
High quality  
For studies of the highest quality, assessors answered yes or no to the following questions  
1.  Subject sampling and precision 
 A. Are the included people representative of the HIV population? (Comment: if people were included 
on the basis of use of ART, gender or insurance claims then they should not be considered 
representative of the HIV population.)  
B. Is the sample size adequate to address the question of prevalence in the studied population? A 
minimum sample size of  100 will be the threshold. 
2 Sampling technique : Were the people recruited at random?  
3 Response rate 
A. Does the article report a response rate in total sample?  
B. Is that response rate 70% or higher?  
4 Exclusion rate 
A. Does the article report an exclusion rate in total sample?  
B. Is the exclusion rate 10% or less?  
5. Measurement and method of determination of kidney disease  
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A. Does the study report the method used for determination of CKD status?  
B. Does the study use a consistent method for determination of CKD status?  
5. Study type – should be a Cohort study 
Medium quality 
 Assessors should answer yes to the following questions: 
1. Participants are not representative of the HIV population, but are representative of a particular group 
within the HIV population (e.g. male/female HIV population, ART – naïve, paediatric population, HIV 
population with no other established risk factor for CKD – Diabetes, Hypertension, obstructive 
uropathy). 
2. If participants were not recruited at random, then were they recruited in a random non-health-care 
convenience method from the entire HIV population?  
3.  Is the study sample size adequate to answer the question of prevalence in the studied population?  
4. Does the study use a consistent method for determination of CKD?  
5. Is it a cross-sectional study? 
Low quality 
For studies of the lowest quality: 
Assessors would be unable to answer yes to all of the above questions. 
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 Only high and medium quality studies will be included in the analysis. 
STATISTICAL ANALYSIS 
The statistical software, Stata 15.1 was used to determine the pooled prevalence of CKD in HIV populations 
both globally and for Sub-Saharan Africa using the random effects model.  The results were presented using 
the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. 
This systematic review protocol was registered with PROSPERO with ID number CRD42016036246. 
 
2.2 SUB-STUDY 2: Determine the prevalence of baseline abnormal kidney function among the HIV 
patients presenting at the HIV clinic in Uyo between January 2002 and December 2016.  
This was a retrospective cohort analysis of data from more than 12,000 incident HIV patients recruited into 
the HIV clinic. Data from the case records of these patients was transferred into Microsoft Excel 2010 and 
anonymized. This data contained the patients’ clinic number; our study number, mobile number, age at first 
presentation, age at the time of data analysis, sex, weight at first presentation, weight at last clinic visit, 
height, BMI at first presentation, serum creatinine at first presentation; other serum creatinine measurements 
and time of measurement, packed cell volume, dipstick urinalysis at first presentation, electrolytes at first 
presentation, HBsAg status, Anti–HCV status, CD4 count at presentation, viral load at presentation, date of 
commencement of ART, ART combination used and any changes in combination, antibiotics and antifungals 
used during follow up, blood pressure at entry and follow up and blood sugar at entry and follow up. Data was 
then transferred into STATA 15.1, StataCorp, College Station, Texas, USA and analyzed.  
 
 




2.3 SUB-STUDY 3: Elucidate the prevalence of traditional risk factors for CKD in the Uyo HIV cohort. 
The aim of this aspect of the study was to determine the prevalence of other traditional CKD risk factors like 
hypertension, diabetes Mellitus, obesity, and dyslipidaemia among the HIV-infected patients.  The case 
definitions of these risk factors are as stated below:  
Hypertension: 2 or more recordings of blood pressure with systolic blood pressure at least 140mmHg and/or 
diastolic blood pressure of at least 90mmHg OR patient who is on antihypertensive medication. 
Diabetes Mellitus: Fasting plasma glucose of at least 7.0mmol/L and/or Random/2-hour post meal plasma 
glucose of at least 11.1 mmol/l OR patient taking oral hypoglycemic agents or insulin 
Obesity: BMI of at least 30kg/m2 in a patient without peripheral oedema. 
Hepatitis B positive: If the surface antigen for Hepatitis B virus is reactive using standard of care kits. 
Hepatitis C positive: If Antibody to Hepatitis C virus is detectable in serum using standard of care laboratory 
techniques. 
 
Identification and recruitment of study participants for urinary TGF-beta and genetic polymorphism study  
The next task was to identify individuals with or without CKD among the cohort of HIV patients attending clinic 
regularly. The sociodemographic, clinical and anthropometric data of the patients was collected at first 
encounter. Ten milliliters of venous blood was drawn for serum creatinine measurement at first encounter, 
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and spot urine collection taken for dipstick urinalysis and urinary protein/creatinine ratios (uPCR). This process 
was repeated 3 months after the initial visit. Every participant with eGFR (as calculated by the Cockcroft-Gault, 
4-variable MDRD and CKD-EPI equations) ≤ 60ml/min/1.73m2 and/or uPCR of ≥ 0.05g/mmol creatinine at 
baseline and by month 3 was deemed to have CKD. At the second clinic visit, venous blood was also drawn for 
DNA extraction and urine sample collected for urinary TGF-beta-1 assay. 
2.4 SUB-STUDY 4:  Investigate the association between Urinary TGF-β1 levels and CKD in the HIV 
population. 
All the incident HIV patients seen at the second clinic visit had 20 mls of spot urine samples collected for 
assessment of urinary TGF-β1 levels using ELISA.  The samples were centrifuged for 5 minutes to remove cells 
and particulate matter and thereafter stored at -70 degrees centigrade in 2 aliquots. At the time of laboratory 
analysis, gentle thawing was performed on one of the urine samples per patient. ELISA was then run on this 
sample and urinary TGF-β1 levels obtained. Urinary creatinine of the same sample will be obtained and urinary 
TGF-β1/creatinine ratio calculated and presented in ng/g creatinine. The urinary TGF-β1/creatinine levels in 
the HIV positive/CKD positive group was compared to that of the HIV positive/ CKD negative group. 
2.5 SUB-STUDY 5: Investigate the association between TGF-β1, APOL1 and HMOX1 gene polymorphisms 
and CKD in the Uyo HIV cohort. 
For those included in the genetic study, patients signed a DNA consent form to allow blood drawn and stored 
for genetic analysis. Approximately, 10mls of blood was drawn and the DNA extracted using standard 
methods. The DNA samples were stored at -20° C in Nigeria and later transported to the Division of Human 
Genetics, University of Cape Town where genetic sequencing was undertaken to determine the allelic and 
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genotype frequencies of the SNPs to be studied. Controls were selected from the same cohort - HIV positive 
individuals without CKD, who are appropriately matched for duration since presentation at the clinic, age and 
sex with the subjects above. Another control group included HIV-uninfected individuals with CKD from other 
aetiology while the population control will consist of individuals from the community without HIV or CKD. 
2.5.1 DNA extraction 
DNA was extracted from whole blood collected into dipotassium EDTA bottles and stored at -20 degrees 
centigrade using the method described in the Quick-DNATM Miniprep Plus kit (Inqaba Biotech). The DNA 
extraction was performed at the University of Niger-Delta PCR laboratory.  
The DNA concentration and purity of each sample was determined using NanoDrop Lite spectrophotometer. 
This spectrophotometer measures optical density to determine DNA concentration, while the absorbance ratio 
(260nm/280nm) is a measure of DNA purity. 
All universal health and safety precautions were followed. The material safety data sheets (MSDS), available 
from the product supplier was strictly adhered to. Genetic sequencing for TGF-β1, APOL1 and HMOX1 risk 
variants was performed at the Human Genetics Laboratory at the University of Cape Town. 
 
Targeted SNPs in TGF-β1, APOL1 and HMOX1 genes 
SNP genotyping of rs1800469, rs1800471, rs1982073, rs121918282 in TGF-β1, rs60910145 (APOL1 G1), 
rs73885319 (APOL1 G1) and rs743811 (HMOX1) was performed using predesigned TaqMan genotyping assays 
(Applied Biosystems, CA, USA). The PCR protocols was performed on the Bio-Rad CFX96 real time PCR system 
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(Bio-Rad laboratories, CA, USA). The rs3074372 (HMOX1) and rs71785313 (APOL1 G2) variants was genotyped 
using fragment analysis, incorporating fluorescently labelled forward primers. The HMOX1 repeats was 
classified as short (</= 25 repeats) or long (>25 repeats) (117). PCR protocols was performed on the Bio-Rad 
thermal cycler T100TM, and analysis of the genotype was achieved using the ABI Prism 3130xl Genetic Analyzer 
(Applied Biosystems, CA, USA). Thereafter, Direct Cycle Sequencing using the ABI Prism 3130xl was performed 
on a subset (10%) of the samples and in order to validate the genotyping results.  
2.5.2 Statistical Analysis 
Descriptive statistical analysis of the prospectively collected patient data was performed using STATA Software 
version 15.1 for WindowsTM (StataCorp, TX, USA). Moreover, this software was utilized to investigate 
associations between clinical variables. A 2 test with one degree of freedom was used to perform the Hardy-
Weinberg equilibrium (HWE). General logistic regression frameworks, adjusted for age and sex, was performed 
to investigate the relationship between genotype results and clinical. P values <0.05 were considered 
statistically significant. 
2.6  ETHICAL CONSIDERATIONS 
Ethical approval for this work was obtained from the University of Uyo teaching Hospital human research ethics 
committee and the UCT Research Ethics Committee (Appendix 2 and 3).  
A written informed consent was obtained from each of the participants for objectives 4 and 5 of this work. 
Participation was voluntary and no patient suffered any penalty for declining to be part of the study. No names 
were recorded on the extracted dataset and questionnaire and a study identification number was assigned to 
each of the participants to ensure proper identification without breaching confidentiality. Data was stored on 
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my personal computer and backed up on my external hard drive and using Cloud storage, both data stores were 
encrypted to ensure no other person except myself and my supervisor has access to the data. This also enhanced 
confidentiality.  
Beneficience was addressed as all results obtained were relayed to the patients and their doctors immediately 
employed these findings to ensure better care for the patients. Also, health education campaigns were 
organized for the participants to help them understand the symptoms of CKD and lifestyle modifications 
(including adherence to ART) that will help reduce the risk of AKI/CKD. Apart from the blood samples taken by 
routine venepuncture, no other invasive procedure was undertaken; therefore, the principle of non-
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CHAPTER 3: CHRONIC KIDNEY DISEASE IN THE GLOBAL HIV-INFECTED POPULATION: A 
SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Chapter 3 is a systematic review and meta-analysis of CKD prevalence in the global HIV-infected population. 
Comparison of prevalence across the World Health Organization (WHO) regions were undertaken with special 
emphasis on sub-Saharan Africa – the epicenter of the HIV pandemic. The paper titled “CHRONIC KIDNEY 
DISEASE IN THE GLOBAL HIV-INFECTED POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS” is 

















































































































































































Search Add to 
Builder 
Query 
#1  Search ((((((Chronic kidney disease) OR CKD) OR Chronic renal insufficiency) OR 
Chronic kidney failure) OR Chronic renal failure) OR Chronic kidney 
insufficiency) OR GFR<60ml/min 
#2  Search (((HIV) OR Human immunodeficiency virus) OR AIDS) OR Acquired 
immune deficiency syndrome 
#3  Search (Prevalence) OR incidence 
#4  Search ("1982/01/01"[Date - Publication] : "2016/09/30"[Date - Publication]) 
 
Web of Science 
Set Web of Science Core Collection 
Search History - 
#1 TS=(Chronic Kidney Disease OR Chronic Renal insufficiency OR Chronic OR chronic Renal failure 
OR  
kidney dysfunction)  
DocType=All document types; Language=All languages; 
#2 TS=(Human Immunodeficiency Virus OR HIV)  
DocType=All document types; Language=All languages; 
#3 #2 AND #1  
DocType=All document types; Language=All languages; 
#4 TS=(Prevalence OR frequency OR incidence)  
DocType=All document types; Language=All languages; 
#5 #4 AND #3  






S2 ("Chronic Kidney Disease+") 
S3 prevalence OR epidemiology OR frequency 
S4 HIV OR human immunodeficiency virus    
S5 AIDS OR acquired immunodeficiency syndrome    
S6 S4 OR S5 ((HIV OR human immunodeficiency virus) OR (AIDS OR acquired 
immunodeficiency syndrome))  
S7 S2 OR Chronic Kidney failure (Chronic Kidney insufficiency OR Renal failure)   
S8 S6 AND S7 (((HIV OR human immunodeficiency virus) OR (AIDS OR acquired 
immunodeficiency syndrome)) AND (Chronic Kidney insufficiency OR Renal failure))  
S9 S3 AND S8 (prevalence OR epidemiology OR frequency) AND (((HIV OR human 
immunodeficiency virus) OR (AIDS OR acquired immunodeficiency syndrome)) AND (Chronic 
Kidney insufficiency OR Renal failure))  
 
AJOL 
Chronic kidney disease) OR CKD) OR Chronic renal insufficiency) OR Chronic kidney failure) OR 
Chronic renal failure) OR Chronic kidney insufficiency) AND renal disease)) AND ((HIV) OR Human 













S3 Table: SCORING CRITERIA FOR QUALITY OF STUDIES (Adapted from Stanifer et al. Lancet Glob 
Health 2014; 2 e174 – 181. 
  CRITERIA QUESTION YES(1) NO (0) 
1 Are the study participants representative of the HIV population in the 
country of study?  
  
2 Did the study exclude individuals with other established risk factors for 
CKD? (These factors may include Hypertension, obesity, underweight and 
Diabetes) 
  
3 Is the sample size adequate (1,000 will be regarded as adequate)   
4 Were the study participants recruited at random? (Non-probability 
sampling methods will be considered inadequate) 
  
5 Was the response rate at least 60% of the initial sample size?    
6 Was the exclusion rate less than 10% of the total sample?   
7 Was eGFR defined as being ≤ 60ml/min/1.73m2 using the MDRD/CKD-EPI 
or Cockroft-Gault formulae?  
  
8 Was prevalence reported by ARV status? (A differentiation of prevalence 
in ARV – naïve patients and those on ARV). 
  
9 Were the sociodemographic characteristics of the study participants 
adequately characterized? 
  
High quality – 7 – 9; Medium quality – 4-6; Low quality – less than 4 
 
 





S4 Table: Assessment of methodological quality of included articles 
AUTHOR NAME STUDY DESIGN Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 TOTAL QUALITY 
Adedeji et al cross-sectional 0 1 0 0 1 1 1 0 1 5 MEDIUM 
Al-Sheikh et al cross-sectional 0 0 0 1 1 0 1 0 1 4 LOW 
Anyabolu et al cross-sectional 1 1 0 1 1 1 1 0 1 7 MEDIUM 
Cao et al cross-sectional 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Caihol et al cross-sectional 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Calza et al cross-sectional 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Campbell et al cross-sectional 1 0 1 1 1 1 1 0 0 6 MEDIUM 
Cheung et al cross-sectional 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Choi et al cross-sectional 1 0 1 1 1 1 1 1 1 8 HIGH 
Cianflone et al cross-sectional 0 0 0 1 1 1 1 1 1 6 MEDIUM 
Colson et al cross-sectional 1 1 0 1 1 1 1 1 1 8 MEDIUM 
Ekat et al cross-sectional 1 0 0 0 0 1 1 0 1 4 LOW 
Fernando et al cross-sectional 1 0 0 1 1 0 1 0 1 5 MEDIUM 
Fischer et al cross-sectional 0 0 1 1 1 1 1 0 1 6 MEDIUM 





George et al nested case-control 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Gonzalez et al cross-sectional 0 0 0 0 1 1 1 0 0 3 LOW 
Gracey et al cross-sectional 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Ibrahim et al retrospective cohort 1 1 1 1 1 1 1 0 1 8 HIGH 
Longo  et al cross-sectional 0 0 0 0 1 1 1 1 1 5 MEDIUM 
Lucas et al retrospective cohort 1 0 1 1 1 1 1 0 0 6 MEDIUM 
Lucas et al2 retrospective cohort 1 1 1 1 1 1 1 0 1 8 HIGH 
Mayor et al retrospective cohort 1 0 1 1 1 1 1 0 1 7 HIGH 
Menezes et al cross-sectional 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Mizushima et al cross-sectional 1 0 0 1 0 0 1 0 1 4 MEDIUM 
Msango et al cross-sectional 1 0 0 0 1 1 1 1 1 6 MEDIUM 
Mulenga LB cross-sectional 1 1 1 1 1 1 1 0 0 7 HIGH 
Nakamura et al retrospective cohort 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Obirikorang et al case-control 1 0 0 1 0 1 1 0 0 4 LOW 
Odongo et al cross-sectional 1 1 0 0 0 0 1 0 1 4 LOW 
Okafor et al cross-sectional 0 1 0 1 1 1 1 0 0 5 MEDIUM 
Overton et al cross-sectional 1 0 0 1 1 0 1 0 1 5 MEDIUM 





Peck et al cross-sectional 1 0 0 1 0 0 1 1 1 5 MEDIUM 
Sarfo et al retrospective cohort 1 0 1 1 1 1 1 1 1 8 HIGH 
Stohr W et al Cohort 1 0 1 1 0 0 1 1 1 6 MEDIUM 
Sorli et al cross-sectional 1 0 1 1 0 0 1 1 0 5 MEDIUM 
Umezudike et al cross-sectional 1 1 0 1 1 1 1 0 0 6 MEDIUM 
Wools-Kaloustian 
etal cross-sectional 1 1 0 1 0 0 1 0 1 5 MEDIUM 
Wyatt et al cross-sectional 1 0 1 1 0 1 1 0 1 6 MEDIUM 
Wyatt et al 
(Rwanda) cross-sectional 0 0 0 1 1 1 1 0 1 5 MEDIUM 
Yanigasawa et al cross-sectional 1 0 0 1 1 1 0 0 1 5 MEDIUM 
Yanigasawa et al cross-sectional 1 0 1 1 1 1 0 0 1 6 MEDIUM 
Zhao et al cross-sectional 1 0 1 1 1 0 1 0 1 6 MEDIUM 
Agbaji et al cross-sectional 0 0 0 1 0 0 1 0 0 2 LOW 
Brennan et al retrospective cohort 0 0 0 1 1 0 1 0 1 4 LOW 
Kamkuemah et al prospective cohort 0 0 1 0 1 0 1 0 0 3 LOW 
Onodugo et al cross-sectional 1 1 0 1 0 0 1 0 0 4 LOW 





Struik et al cross-sectional 1 0 0 1 1 1 1 0 0 5 MEDIUM 
Acchra et al prospective cohort 0 0 1 1 1 1 1 0 1 6 MEDIUM 
Bandera et al prospective cohort 1 0 1 1 1 1 1 1 1 8 HIGH 
Bonjoch et al cross-sectional 1 0 0 1 1 1 1 0 1 6 MEDIUM 
Estrella et al Cross-sectional 1 0 0 0 1 1 1 0 1 5 MEDIUM 
Zachor et al retrospective cohort 0 0 0 1 1 1 1 0 1 5 MEDIUM 
Santiago et al 
Cross-sectional 
1 0 1 1 1 1 1 1 1 8 MEDIUM 
Sakajiki et al cross-sectional 0 0 0 1 1 1 1 0 0 4 LOW 
Schoffelen et al cross-sectional 1 0 1 1 1 1 1 0 1 7 HIGH 
Fulop et al cross-sectional 1 0 0 1 1 1 1 1 1 7 HIGH 
Hsieh et al cross-sectional 1 0 0 1 0 0 1 1 0 4 LOW 









S5 Table: Summary statistics from meta-analyses of prevalence studies on CKD in people with HIV using random effects model and arcsine 
transformations 




















Gender            
 Overall        0.007   
  MDRD 19 147,637 6,612 4.7 (3.6 – 6.0) 97.6 <0.001  0.93 0.48 
  CKD-EPI 3 4,599 164 3.3 (2.5-4.3) 32.7 <0.001  <0.001 0.36 
  CG 9 6,205 674 12.0 (5.0-21.3) 98.1 <0.001  0.41 0.44 
 Male        <0.001   
  MDRD 9 73,489 3,297 4.9 (3.1-7.0) 98.8 <0.001   0.55 
  CKD-EPI 1 1,970 74 3.9 (3.0-5.1) - <0.001   - 
  CG 4 2,773 254 8.3 (1.1-20.8) 96.6 <0.001   0.12 
 Female        0.005   
  MDRD 10 74,148 3,315 4.5 (3.3-5.8) 85.9 <0.001   0.72 
  CKD-EPI 2 2,629 90 3.0 (2.1-3.9) 98.4 <0.001   - 
  CG 5 3,432 420 15.2 (4.9-29.7) 98.7 <0.001   0.34 
ARV status            
 Overall        <0.001   
  MDRD 21 105,846 3,688 5.4 (4.5-6.4) 96.8 <0.001  0.19 0.02 
  CKD-EPI 7 35,330 780 3.0 (1.8-4.5) 97.4 <0.001  0.52 0.30 
  CG 8 32,073 2,824 10.4 (7.3-14.1) 97.6 <0.001  0.27 0.48 
 ARV – naïve        0.06   
  MDRD 5 43,720 1,591 9.0 (3.0-17.7) 98.7 <0.001   0.22 
  CKD-EPI 4 13,033 295 3.6 (1.1-7.4) 98.5 <0.001   0.41 
  CG 5 5,634 508 12.4 (5.4-21.8) 98.5 <0.001   0.18 
 ARV - exposed        0.002   
  MDRD 16 62,126 2,097 4.6 (3.7-5.6) 95.1 <0.001   0.02 
  CKD-EPI 3 22,297 485 2.5 (1.3-4.0) 90.1 <0.001   0.67 
  CG 3 26,439 2,316 7.8 (5.2-10.8) 89.2 <0.001   0.65 
CD4 COUNT            
 Overall        0.007   
  MDRD 37 147,185 7,799 6.2 (4.9-7.7) 98.8 <0.001  0.37 0.22 





  CG 15 54,251 4,895 12.7 (8.1 – 18.1) 99.3 <0.001  0.33 0.19 
 <200 cells/ul        0.09   
  MDRD 8 40,815 1,787 6.2 (4.9-7.7) 98.8 <0.001   0.37 
  CKD-EPI 3 5,750 523 4.4 (2.2-7.3) 97.1 <0.001   0.48 
  CG 4 32,186 3,785 17.9 (6.5-33.4) 98.7 <0.001   0.44 
 ≥ 200 cells/ul        0.02   
  MDRD 29 107,339 2,708 6.5 (4.9 – 8.4) 99.1 <0.001   0.34 
  CKD-EPI 9 28,295 617 3.9 (2.2-6.1) 99.1 <0.001   0.11 
  CG 11 22,065 1,110 11.0 (6.1-17.0) 99.8 <0.001   0.007 
 <350 cells/ul        0.02   
  MDRD 24 139,241 7,262 6.0 (4.4-7.3) 88.6 <0.001   0.37 
  CKD-EPI 6 26,983 992 5.0 (1.6-10.1) 97.5 <0.001   0.40 
  CG 12 36,319 4,345 14.6 (8.8-21.4) 97.2 <0.001   0.31 
 ≥350 cells/ul        0.16   
  MDRD 13 8,913 596 6.0 (4.4-7.8) 99.3 <0.001   0.51 
  CKD-EPI 6 7,062 148 3.9 (1.0-8.3) 99.2 <0.001   0.15 
  CG 3 17,932 550 6.3 (2.2-12.3) 99.4 <0.001   0.14 
Age, median 
38.5 years 
           
 Overall        0.003   
  MDRD 44 166,157 9,234 6.4 (5.2-7.7) 98.9 <0.001  0.54 0.16 
  CKD-EPI 14 41,791 1,398 4.8 (2.9-7.1) 98.7 <0.001  0.98 0.15 
  CG 19 59,414 5,308 12.3 (8.4-16.7) 99.5 <0.001  0.17 0.15 
 Above median        0.33   
  MDRD 27 78,099 5,799 6.1 (4.6-7.9) 98.7 <0.001   0.66 
  CKD-EPI 6 4,395 200 4.8 (2.3-8.2) 91.8 <0.001   0.52 
  CG 6 43,844 2,906 8.5 (4.5-13.6) 99.4 <0.001   0.69 
 Below Median        0.03   
  MDRD 17 87,190 3,455 6.9 (5.2-8.8) 98.7 <0.001   0.02 
  CKD-EPI 8 37,396 1,198 4.8 (2.6-7.5) 99.2 <0.001   0.26 
  CG 13 15,570 2,402 14.2 (7.9-21.9) 99.3 <0.001   0.95 
Hypertension             
 HIV/No HTN        -   





  CKD-EPI 1 3,746 198 5.3 (4.6-6.0) - -   - 
  CG - - - - - - - - - 
 HIV/HTN           
  MDRD 10 7,012 1,118 20.7 (14.3-27.8) 95.6 <0.001 - - 0.29 
  CKD-EPI 1 891 88 9.9 (8.1-12.0) - -   - 




           
 Overall        0.08   
  MDRD 23 55,920 4,897 5.3 (3.8-7.0) 98.2 <0.001  0.30 0.02 
  CKD-EPI 9 17,564 453 3.3 (1.8-5.2) 96.8 <0.001  0.42 0.19 
  CG 6 19,289 826 10.4 (3.5-20.4) 99.1 <0.001  <0.001 0.10 
 Above median        <0.001   
  MDRD 12 21,638 1,495 6.2 (4.2-8.5) 96.7 <0.001   0.60 
  CKD-EPI 6 8,870 216 3.9 (1.3-7.6) 97.9 <0.001   0.11 
  CG 1 723 47 6.5 (4.9-8.5) - -   - 
 Below median        0.05   
  MDRD 11 34,941 3,402 4.3 (2.2-7.2) 98.7 <0.001   0.04 
  CKD-EPI 3 8,694 237 2.7 (2.4-3.0) 0.0 <0.001   0.09 
  CG 5 18,566 779 11.3 (2.6-24.8) 99.1 <0.001   0.14 
Diabetes            
 HIV/ No DM           
  MDRD 10 22,620 1644 8.4 (5.5-11.8) 98.2 <0.001 - <0.001 0.38 
  CKD-EPI 2 11,702 456 3.7 (3.4-4.1) 99.1 <0.001   - 
  CG - - - - - -   - 
 HIV/DM           
  MDRD 10 2403 339 19.4 (13.5-26.0) 83.6 <0.001 - - 0.08 
  CKD-EPI 2 320 36 11.2 (8.0-15.0) 99.1 <0.001   - 








           
 Overall        0.06   
  MDRD 23 60,538 5,172 5.5 (4.0-7.1) 98.2 <0.001  0.19 0.02 
  CKD-EPI 9 17,564 453 3.3 (1.8-5.2) 96.8 <0.001  0.06  
  CG 6 19,760 870 10.4 (3.8-19.7) 99.1 <0.001  <0.001  
 Above median        <0.001   
  MDRD 14 48,857 4,618 6.1 (4.3-8.3) 98.4 <0.001   0.06 
  CKD-EPI 4 3,263 165 5.6 (2.3-10.2) 94.5 <0.001   0.53 
  CG 1 723 47 6.5 (4.9-8.5) - -   - 
 Below median        0.02   
  MDRD 9 11,681 554 4.4 (3.0-6.2) 91.3 <0.001   0.84 
  CKD-EPI 5 14,301 288 2.0 (0.8-3.8) 96.7 <0.001   0.90 
  CG 5 19,037 823 11.2 (3.1-23.4) 99.3 <0.001   0.11 
Hepatitis B            
 HIV/ No HBV        <0.001   
  MDRD 13 82,428 2,747 7.5 (5.5-9.8) 98.8 <0.001  0.89 0.02 
  CKD-EPI 4 31,008 912 3.6 (2.0-5.6) 98.3 <0.001   0.33 
  CG 1 419 101 24.1 (20.3-28.4)     - 
 HIV/HBV        0.004   
  MDRD 13 5,741 236 7.2 (4.4-10.5) 90.2 <0.001   0.01 
  CKD-EPI 4 1,574 30 2.3 (0.8-4.3) 64.5 0.04  0.44 0.21 





           
 Overall        0.03   
  MDRD 18 66,090 4,376 4.3 (2.5-6.5) 99.2 <0.001  0.98 0.33 
  CKD-EPI 6 34,969 728 2.0 (1.1-3.1) 96.4 <0.001  0.81 0.88 





 Above median        0.03   
  MDRD 10 17,010 883 4.3 (3.1-5.6) 92.3 <0.001   0.49 
  CKD-EPI 2 845 18 2.1 (1.2-3.2) 99.3 <0.001   - 
  CG 2 17,327 577 3.0 (2.8-3.3) 99.6 <0.001   - 
 Below median        <0.001   
  MDRD 8 49,080 3,493 4.3 (1.3-8.9) 99.7 <0.001   0.64 
  CKD-EPI 4 34,124 710 2.0 (1.0-3.4) 97.8 <0.001   0.84 
  CG 2 968 59 6.0 (4.6-7.7) 99.6 <0.001   - 
Hepatitis C            
 HIV/No HCV        <0.001   
  MDRD 14 71,799 2,695 7.3 (5.6-9.3) 98.3 <0.001  0.74 0.01 
  CKD-EPI 4 29,286 842 3.5 (1.9-5.5) 98.2 <0.001   0.36 
  CG 1 433 101 23.3 (19.6-27.5) -     
 HIV/HCV        0.06   
  MDRD 14 11,183 598 7.6 (4.5-11.4) 97.1 <0.001   0.10 
  CKD-EPI 4 3,649 93 3.7 (1.8-6.2) 87.3 <0.001  0.78 0.08 




median – 11% 
           
         0.03   
 Overall MDRD 21 109,968 5,914 4.5 (3.0-6.2) 99.2 <0.001  0.18 0.96 
  CKD-EPI 6 35,102 752 2.3 (1.4-3.6) 96.9 <0.001  0.72 0.56 
  CG 4 18,295 636 8.1 (1,9-17.9) 98.8 <0.001   0.29 
 Above median        <0.001   





  CKD-EPI 2 7,580 209 2.6 (2.3-3.0) 99.3 <0.001   - 
  CG 2 1,214 164 12.4 (10.6-14.3) 99.6 <0.001   - 
 Below median        0.39   
  MDRD 9 27,509 722 3.5 (2.3-4.8) 93.2 <0.001   0.16 
  CKD-EPI 4 27,522 543 2.4 (1.0-4.3) 97.8 <0.001   0.58 
  CG 2 17,081 472 2.7 (2.4-2.9) 99.6 <0.001   - 













S1 Fig. Forest plot showing the pooled prevalence of CKD in HIV populations for studies with at least two 











S2 Fig. Funnel plots for studies with two or more eGFR values. 
 
 






S3 Fig. Forest plot showing pooled prevalence for studies with two or more MDRD-based eGFR estimates 










Chapter 3 showed a higher prevalence of CKD in Sub-Saharan Africa compared with other 
WHO regions. Within Africa, West Africa had the highest recorded prevalence. There was 
high heterogeneity in the prevalence across the regions which could be explained by WHO 
region, co-morbid hypertension and diabetes mellitus levels but not by gender, hepatitis B, 
hepatitis C, CD4 count or antiretroviral use status. 
Having seen the global picture and documented the burden of CKD in the global HIV-infected 
population, it became imperative to document the CKD prevalence in the HIV population 














CHAPTER 4:  PREVALENCE AND CORRELATES OF CHRONIC KIDNEY (CKD) 
AMONG ART-NAÏVE HIV PATIENTS IN THE NIGER-DELTA REGION OF NIGERIA 
 
Chapter 4 is a 15-year analysis among ART-naïve patients presenting at the University of Uyo 
Teaching Hospital HIV clinic. The prevalence of CKD in this population was documented and 
factors associated with CKD occurrence elucidated. This is presented in a manuscript format 
entitled “Prevalence and correlates of Chronic kidney disease (CKD) among ART-naïve 
patients in the Niger-Delta region of Nigeria” as published by Medicine (Baltimore) and 

























































The prevalence of CKD in this HIV population was high – 13.4% (95%CI 11.6-15.4%). Increasing 
age and CD4 count less than 200 cells/µL were independently associated with CKD occurrence 
among this patient populace. This high CKD prevalence may partly be due to co-morbidities 
like hypertension and diabetes mellitus among these patients though at multivariable level, 
they did not show statistical significance. Therefore, the next chapter deals with the 
prevalence of traditional CVD risk factors in this HIV population. 






CHAPTER 5: PREVALENCE AND CORRELATES OF TRADITIONAL RISK FACTORS 
FOR CARDIOVASCULAR DISEASE IN A NIGERIAN ART-NAÏVE HIV POPULATION: 
A CROSS-SECTIONAL STUDY 
 
Chapter 5 explores important co-morbidities that have been established as traditional risk 
factors for cardiovascular disease – hypertension, diabetes mellitus, obesity and 
dyslipidaemia. Their prevalence is documented and associations with these risk factors 
sought. The findings have been published by BMJ open with the title “Prevalence and 
correlates for cardiovascular disease in a Nigerian ART-naïve HIV population: A cross-sectional 
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Table 2: CVD risk factor prevalence across age groups and by gender 
   Male     Female     All   
Age (years) < 20 20-39 40-59 ≥ 60 p < 20 20-39 40-59 ≥ 60 p < 20 20-39 40-59 ≥ 60 p 










































































































































































































DM 0 (0.0) 27 (6.1) 22 (7.1) 3 (13.6) 0.27 1 (4.2) 27 (3.5) 20 (8.8) 1 (5.3) 0.01 1 (4.0) 54 (4.5) 42 (7.8) 4 (9.8) 0.003 
Underweight 1 (14.3) 129 
(12.4) 




89 (12.5) 15 
(22.1) 
0.39 16(27.1) 417 (11.6) 169 (11.6) 17 (13.9) 0.54 








382 (53.7) 39 
(57.4) 
0.82 38 (64.4) 2075 (57.9) 834 (57.2) 75 (61.5) 0.81 




9 (16.7) 0.01 4 (7.7) 611 
(24.0) 
163 (22.9) 12 
(17.7) 
0.80 5 (8.47) 786(21.9)  335(23.0) 21(17.2) 0.48 
Obesity 0 (0.0) 31 (3.0) 42 (5.6) 7 (12.9) 0.001 0 (0.0) 275 
(10.8) 




High CI 1 












































































































HTN-Hypertension; ISH-Isolated Systolic Hypertension; IDH-Isolated Diastolic Hypertension; DM-Diabetes Mellitus; TC-Total Cholesterol; LDL-c=Low density lipoprotein; HDL-c = High 











































Chapter 5 had shown a high prevalence of hypertension, diabetes mellitus and dyslipidaemia 
in a relatively young HIV-infected population. This, in addition to the HIV disease, puts these 
patients at a high risk of CKD and/or other target organ damage. Early diagnosis of CKD in the 
HIV population is critical, especially in the setting of poor health infrastructure, to prevent 
progression to ESRD. 





CHAPTER 6: Urinary Transforming Growth Factor-Beta 1 (uTGF-β1) and 
prevalent chronic kidney disease risk in HIV-positive patients in West Africa  
 
The early identification of CKD among adults with HIV disease, especially in Sub-Saharan 
Africa, may be one of the important public health interventions to prevent the rising 
incidence of ESRD in the HIV population. At present, clinicians depend on urine albumin-
creatinine ratio with the occurrence of persistent microalbuminuria being the earliest 
manifestation of CKD.  In nephropathies associated with expansion of the intracellular 
matrix (like HIV-related nephropathy), increased expression of TGF-β1 is known to occur in 
the proximal tubular cells. This may be useful for the early diagnosis of CKD, either alone or 
in combination with microalbuminuria. 
Chapter 6 investigates the association between urinary TGF-β1 and prevalent CKD in the 
adult HIV population. This manuscript has been submitted and is currently undergoing 
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This study investigated the association of urinary transforming growth factor-β1 (uTGF-β1) 
with prevalent chronic kidney disease (CKD) in the HIV-infected population.   
METHODS 
HIV-positive patients without CKD (HIV+CKD-, n=194) and 114 with CKD (HIV+CKD+) who did 
not have hypertension, diabetes mellitus, Hepatitis B or C, had their urinary protein-
creatinine ratio (uPCR), serum TGF-β1 and uTGF-β1 measured. Urinary TGF-beta-creatinine 
ratios (uTGF-β1Cr) were calculated. Spearman correlation was employed to determine the 
association between uTGF-β1Cr and various attributes while the Cuzick trend test was used 
to assess the presence of a linear trend in median uTGF-β1Cr levels across the stages of CKD. 
Multivariable robust linear regression models were used to assess independent association 
with variability in uTGF-β1Cr and eGFR levels.   
RESULTS 
The age of the participants was 38.3±10.3 years with 73.4% being female. The median uTGF-
β1Cr was higher among HIV+CKD+ [4.85 ng/mmol (25th-75th percentile 1.96-12.35) versus 
2.95 (1.02-5.84); p=0.001)]. There was significant positive correlation between uTGF-β1Cr 
and age (p=0.02), negative correlation with eGFR (p=0.001) and positive correlation with 
uPCR (p<0.001) in the HIV+CKD+ group. Among the HIV+CKD+ patients, there was gradual 
reduction in the median level of uTGF-β1Cr with CKD severity (p=0.04).  





HIV+CKD+ patients had significantly higher levels of uTGF-β1Cr after controlling for potential 
confounders. Using eGFR as dependent variable, proteinuria explained the changes 
associated with uTGF-β1Cr levels. 
CONCLUSION 
HIV+CKD+ patients express higher levels of uTGF-β1 especially in the early stages of CKD 
which is strongly associated with proteinuria.   
 
INTRODUCTION  
The early diagnosis and treatment of chronic kidney disease (CKD) presents a definite 
opportunity for reducing the incidence of end-stage renal disease (ESRD). This is especially 
important in regions of high HIV prevalence which unfortunately, tend to have dysfunctional 
health care systems. Transforming growth factor beta-1 (TGF-β1) is a 112-amino acid, 25KDa 
ubiquitous protein believed to play a central role in renal fibrosis1 both as a proliferative, 
and in some conditions anti-proliferative factor.2   
In diabetic nephropathy, overexpression of TGF-β1 has been found to occur in the kidneys 
and in-vivo studies have documented increased expression of TGF-β1 in proximal tubular 
cells and mesangial cells cultured in high glucose concentrations.3 Also, in 
glomerulosclerosis, TGF-β1 has been observed to be centrally involved in extracellular 
matrix expansion.4  





Indeed, renal disease associated with expansion of extracellular matrix (diabetic 
nephropathy, lupus nephritis, focal and segmental glomerulonephritis and IgA nephropathy) 
have all been associated with increased expression of TGF-β1 while renal conditions that do 
not have extracellular matrix accumulation (thin basement membrane disease, minimal 
change disease) seem not to have increased expression of TGF-β1.5 The former may be the 
case with HIV-related nephropathy where expansion of the extracellular matrix occurs. 
Studies have shown that the administration of anti-TGF-β1 substances attenuate 
extracellular matrix production 6,7 and may lead to retardation of CKD progression in renal 
diseases associated with increased extracellular matrix production.  
Some studies in HIV-positive patients with CKD have demonstrated elevated levels of TGF-β1 
in renal tissue,8 serum 9 and in the urine 10 of HIV-associated nephropathy (HIVAN) patients. 
Our study aim was to investigate the association of uTGF-β1 with prevalent CKD in HIV-
positive patients in Nigeria.  
METHODS  
Study Participants  
This was a cross-sectional study involving 194 HIV-positive patients without CKD (HIV+CKD-) 
and 114 HIV-positive patients with CKD (HIV+CKD+) seen at the HIV clinic and the renal unit 
of the University of Uyo Teaching Hospital, Nigeria (Ethical review number: 
UUTH/AD/S/96/VOL.XIX/15). The facility’s HIV clinic offers care to about 50 ambulant HIV-
positive patients daily with about three thousand five hundred patients on active 
enrollment.  





Screening for renal disease is not routinely done because patients pay out-of-pocket. 
Ambulant HIV-positive patients on antiretroviral (ARV) treatment at the HIV clinic who gave 
informed consent were recruited into the study. CKD was defined as eGFR of < 
60ml/min/1.73m2 persisting in two measurements at least 3 months apart and/or urine 
protein-creatinine ratio (uPCR) of ≥ 0.05 g/mmol creatinine.11 The patients’ 
sociodemographic (age, gender, ethnicity) and clinical characteristics (e.g. BMI and blood 
pressures) were collected using standard techniques. Data regarding the patients’ CD4 count 
at initiation of care and current CD4 count levels, viral load at initiation of care and current 
levels and antiretroviral (ARV) regimen were also collected. All patients were on ARVs. The 
ARV regimen used in this program included zidovudine-based regimens (AZT-3TC-EFV or 
AZT/3TC/NVP); tenofovir-based regimen (TDF-3TC-EFV or TDF-FTC-EFV); abacavir-based 
regimen (ABC-3TC-EFV) and less frequently, protease-inhibitor regimen. Patients with 
hypertension, diabetes mellitus; hepatitis B or C co-infection were excluded from the study.   
Spot urine samples for uTGF-β1 assay were collected, processed and stored using the 
manufacturer’s instructions. All samples were centrifuged with the supernatant stored in 2 
aliquots at -20 degrees centigrade within 2 hours of collection. Blood samples (4 ml) were 
collected, serum separated and stored in 2 aliquots (for serum creatinine and TGF-β1 assay). 
Serum and urine creatinine were measured with RANDOX creatinine kits (RANDOX, UK) 
using the modified Jaffe’s reaction. Serum and urinary TGF-β1 were measured using 
Biovision (California, USA) TGF-β1 (human) ELISA kit (catalog # K4342-100) in duplicates.  
The intra-assay and inter-assay coefficient of variation was 8.6% and 7.0% respectively. The 
sensitivity of the assay was < 1pg/ml.  





To ameliorate the effect of varying urine concentrations, urinary TGF-β1/creatinine ratio 
(uTGF-β1Cr, pg/mmol) was derived by dividing urinary TGF-β1 (in pg/L) by urinary creatinine 
(in mmol/L) and later converted to ng/mmol. We estimated GFR using the 4-variable MDRD 
12 and the CKD-EPI 13 equations. Participants’ kidney function was staged using the Kidney 
Disease Outcome Quality Initiative (K/DOQI) classification.11  
All data analysis was performed with Stata 15.1 (StataCorp, Texas, USA). Numerical variables 
were reported as means (± standard deviation) or median (25th-75th percentile). Categorical 
variables are reported as frequencies (percentages). Comparison of quantitative variables 
was performed using students t-test (or its non-parametric equivalent, the Mann-Whitney U 
test). Comparison of categorical variables was performed using the Chi-square test. The 
spearman rank correlation test was used to investigate the continuous association between 
uTGF-β1Cr and certain demographic and clinical variables (age, serum creatinine, serum 
TGF-β1, uPCR and CD4 count) and a formal comparison of the correlation coefficients 
undertaken using the Stata module for comparison of correlation coefficients based on the 
Steiger’s test.14 The Cuzick trend test was used to assess the presence of a linear trend in 
median uTGF-β1Cr levels across the stages (1 – 5) of CKD. Univariable and multivariable 
robust linear regression models were built to determine factors independently associated 
with variability in uTGF-β1Cr and eGFR levels. The Akaike information criteria (AIC) was used 
to determine the best multivariable model that explains the variability in uTGF-β1Cr levels. 
p-value less than 0.05 was deemed statistically significant.   
 






Demographic and clinical characteristics  
One hundred and ninety-four HIV+CKD- and 114 HIV+CKD+ were recruited into the study. The 
mean age of the participants was 38.3 ± 10.3 years with statistically significant difference 
between the groups (p=0.02). The gender distribution showed a female preponderance 
(73% versus 27%). Table 1 summarizes the demographic and clinical characteristics of the 
study participants by CKD status. The level of serum TGF-β1 and urinary TGF-β1 was higher 
among the HIV+CKD+ patients than in HIV+CKD- patients, though this difference did not 
achieve statistical significance. However, when urinary TGF-β1 level was standardized by 
using the urinary TGF-β1/creatinine ratio, those with HIV+CKD+ had significantly higher levels 
(Table 1).  
Factors associated with uTGF-β1Cr   
Age and uPCR had significant correlation with uTGF-β1Cr while no significant correlation was 
found with mABP, BMI, CD4 count and serum TGF-β1 for the total study population (Table 
2). However, in the HIV+CKD+ group there was significant correlation with age, serum 
creatinine, uPCR and eGFR. There was significant positive correlation between uPCR and 
uTGF-β1Cr (rho=0.32; p<0.001). A significantly higher correlation was found between uTGF-
β1Cr and eGFR in the HIV+CKD+ group than the HIV+CKD- group. For the HIV+CKD+ group, 
median uTGF-β1Cr significantly decreased with severity of CKD (Figure 1).  
 





There was no correlation between serum TGF-β1 and eGFR (Rho = -0.04; p=0.52) nor 
between serum TGF-β1 and serum creatinine (Rho = 0.09; p=0.19). 
Univariable and multivariable linear regression models  
After adjusting for the effect of age at the time of data collection, gender differences, mean 
arterial blood pressure, waist circumference, eGFR, ARV regimen and CD4 count at 
enrollment, patients with HIV+CKD+ persistently had higher levels of uTGF-β1Cr compared 
with HIV+CKD- (Table 3). The magnitude of the effect of uPCR on uTGF-β1Cr levels was noted 
to be much higher than that of eGFR. The type of ARV regimen administered, differences in 
gender, BMI, CD4 count and serum TGF-β1 were not significantly associated with uTGF-β1Cr 
at the multivariable level (Table 3). Older age was significantly associated with higher uTGF-
β1Cr levels. A little more than a quarter [88 (28.6%)] of the sample population were on TDF. 
Sensitivity analysis done (without patients using TDF) did not show any significant qualitative 
difference. All independent associations seen in the initial model were maintained. 
Table 4 shows univariable and multivariable robust linear regression models with eGFRCKD-EPI 
as dependent variable. The relationship between uTGF-β1Cr and renal function seen in 
previous analysis appears to be dependent on proteinuria levels. In both multivariable 
models, serum TGF-beta was not independently associated with uTGF-β1Cr or eGFRCKD-EPI, 
Tables 3 and 4. 
 
 






This study found significantly higher levels of uTGF-β1Cr in HIV+CKD+ patients compared to 
HIV+CKD- patients even after controlling for other potential confounders. This difference also 
occurred despite both groups having similar levels of serum TGF-β1. There was significant 
positive correlation between uTGF-β1Cr and uPCR. Older age and eGFR were also 
independently associated with differences in uTGF-β1Cr levels. Among the HIV+CKD+ 
individuals, the levels of uTGF-β1Cr progressively decreased across CKD stages 1 to 5. 
Ultimately, uTGF-β1Cr levels were fully dependent on uPCR levels.  
TGF-β1 is known to induce renal fibrosis through multiple pathways including direct action 
on fibroblasts and other cells that cause extracellular matrix synthesis; inhibition of anti-
fibrotic pathways and induction of cell loss through apoptosis 15. In the “canonical” pathway 
of TGF-β1-induced renal fibrosis, the binding of TGF-β1 to its twin transmembrane receptors 
leads to the activation (phosphorylation) of smad2 and smad3 which is then translocated to 
the nucleus with the help of smad4 protein. The activation of smad2 and smad3 is usually 
associated with the inhibition of smad7 which is known to have anti-fibrotic activity. The 
binding of smad3 to gene promoters leads to transcription of profibrotic molecules. This 
leads to increased laying down of extracellular matrix in the kidneys and subsequent 
fibrosis.15 In the kidneys, TGF-β1 is expressed on the renal tubular epithelial cells and 
glomerular basement membrane 16 and also in the myofibroblasts occurring in the 
interstitium during chronic kidney injury.5 The increased expression of TGF-β1 in persistent 
renal injury 17 manifests as increased urinary excretion of TGF-β1.18  





This has been documented in renal diseases associated with increase in extracellular matrix 
production 6,7 including HIV-related nephropathy.10 The finding of increased urinary 
excretion of TGF-β1 in HIV patients with CKD was corroborated by our study. Others have 
also found a positive correlation between urinary albumin excretion and uTGF-β1 19 which 
was also corroborated by our study. Indeed, we observed a stronger effect of uPCR 
(compared to eGFR) on uTGF-β1Cr levels in this study. This is probably due to the activation 
of proximal tubular cells by persistent proteinuria leading to increased production of TGF-
β1.20 In the multivariable model with eGFR as the dependent variable, uPCR was shown to 
clearly explain the changes associated with uTGF-β1Cr.  
We also noted a step-wise reduction in urinary TGF-β1 levels in individuals with more severe 
CKD (stages 4 and 5). In advanced CKD where tubular atrophy and severe tubulointerstitial 
fibrosis has set in, there is reduced numbers of myofibroblasts and functional proximal 
tubular epithelial cells (and thus TGF-beta expression) in the tubulointerstitium which may 
lead to reduced excretion of urinary TGF-β1. This explanation suggests a type of “burn-out” 
of TGF-β1 activity as CKD progresses. Some investigators have reported lower interstitial 
density measurements for TGF-β1 in advanced CKD from HIV-associated nephropathy 
(HIVAN) and diabetic nephropathy patients compared with HIV-positive and HIV-negative 
controls.21 Similarly, some studies have shown a reduction in circulating TGF-β1 and TGF-β1 
mRNA in end-stage kidney disease patients.22-24 A 12-month follow up study 25 among CKD 
patients with a wide range of aetiology (not including HIV), found significantly higher levels 
of tubulointerstitial TGF-β1 mRNA in renal disease patients who did not have progressive 
CKD compared to those who had progressive CKD.  





This suggested a protective effect of TGF-β1 but a 12-month follow up period may not be 
adequate to assess long term renal outcomes and serial TGF-β mRNA measures were not 
available in this study. Studies with contrary findings 26,27 (higher TGF-β1 
immunohistochemical and mRNA expression in the renal tubulo-interstitium with increased 
fibrosis) were noted to have been done in patients with stages 1 to 3 CKD and not very 
advanced disease. Indeed, one study 26 used only patients with serum creatinine less than 
2.0 mg/dl (about 177 µmol/L), understandably because of the risk involved in the biopsy of 
fibrotic kidneys. It appears that serial measurements of urinary TGF-β1 in progressive 
HIV+CKD+ patients, being a non-invasive procedure, may more succinctly, document the 
temporal profile of uTGF-β1 in progressive CKD.  
The markedly elevated uTGF-β1Cr found in patients in stages 1 and 2 CKD present a window 
of opportunity to reverse or slow down progression if early diagnosis is made and available 
intervention like angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor 
blockers (ARBs) are employed. Studies have shown reduction in uTGFβ1 levels attributable 
to administration of ACE-I 28 or prednisolone 29 in IgA nephropathy. The actions of these 
medications may not be unconnected with the fact that persistent proteinuria is known to 
activate complements in the renal tubular epithelial cells leading to a cascade of events that 
eventuate in renal fibrosis.30,31 Reducing proteinuria using ARBs or ACE-I may indirectly 
reduce TGF-β1 profibrotic activity in the kidneys and slow down CKD progression. However, 
it is yet to be shown, in a properly conducted clinical trial, that this will be the case among 
HIV patients with early CKD. The type of ARV regimen used did not appear to have any effect 
on variability in uTGF-β1Cr levels in this study.  





This includes tenofovir use, which has been known to be associated with proximal tubular 
dysfunction. We are not aware of any direct link between tenofovir-related renal fibrosis 
and TGF-β1 levels. It may also have been more informative to compare uTGF-β1Cr levels 
between ARV-naïve and ARV-exposed patients. Unfortunately, all patients in this study had 
been commenced on ARV.        
A major limitation of this study is the lack of renal histopathology among the patients with 
CKD. This could have determined if the degree of fibrosis (glomerular, tubular and 
interstitial) correlated with uTGFB1 in the CKD population. Another limitation of our study is 
the cross-sectional design as this design does not allow for serial assessment of this marker 
as a measure of progressive deterioration of kidney function. Therefore, it is difficult to 
ascertain from this work if uTGF-β1Cr increase predates the occurrence of persistent 
proteinuria. Again, because the levels of uTGF-β1Cr appear to wane with advanced CKD, it is 
possible to miss cases of advanced CKD if this test is used as a stand-alone. Also, the lack of 
HIV negative controls limited comparison of uTGF-β1Cr levels in the HIV patients and the 
general population. Despite the limitations, the result of our study is an important addition 
to current body of literature and suggest that uTGF-β1Cr is an important marker of CKD in 
HIV positive patients. Whether this biomarker can be useful for monitoring kidney response 










HIV patients with CKD express higher levels of TGF-beta-1 activity in urine especially in the 
early stages of CKD explained by proteinuria levels. Persistent proteinuria remains a 
veritable tool for early CKD detection in the HIV population. 
  

















































Age (years) 38.3±10.3 39.9±10.4 37.1±10.1 0.02 
Female gender  [n (%)] 226 (73.4) 85 (74.6) 141 (72.7) 0.72 
Duration on ARV (25th-75th percentile) 5 (2-8) 5 (2-8) 5 (2-8) 0.27 
Systolic blood pressure (mmHg) 129.0±26.3 137.0±26.9 124.5±24.8 <0.001 
Diastolic blood pressure (mmHg) 77.7±14.5 80.8±14.5 75.2±14.1 0.001 
Mean arterial pressure (mmHg) 91.2±13.9 93.0±13.5 90.1±14.1 0.07 
Weight (kg) 61.4 ±11.9 59.1±11.5 62.7±12.0 0.01 
Height (m) 1.63 ± 0.09 1.63±0.08 1.63±1.0 0.38 
Body mass index (kg/m2) 23.2±4.4 22.5±4.4 23.6±4.4 0.03 
Waist circumference (cm) 80.1±9.5 79.3±9.2 81.3±9.6 0.07 
Serum creatinine (µmol/L) 85.3 (67.6-108.8) 110.8 (90-144) 74 (61-88) <0.001 
eGFRCKD-EPI (ml/min/1.73m2) 80.3 (58.6-105.1) 56.1 (41.9-75.1) 97.6 (78.3-113.3) <0.001 
eGFRMDRD(ml/min/1.73m2) 74.7 (55.8-97.9) 53.9 (39.9-69.5) 90.2 (72.5-111.2) <0.001 
uPCR (g/mmol creatinine) 0.04 (0.02-0.09) 0.11 (0.03-0.20) 0.03 (0.02-0.04) <0.001 
CD4 count at enrollment (cells/µL) 207 (80-380) 226 (69-384.5) 197 (89-372) 0.84 
Current CD4 count (cells/µl) 499 (308-693) 472.5 (274-675) 500 (329-714) 0.32 
Current Log viral load (copies/ml) 2.9±1.5 2.8±1.4 3.0±1.6 0.49 
Chronic kidney disease stage [n (%)]     
1  18 (15.8)   
2  30 (26.3)   
3  48 (42.1)   
4  8 (7.0)   
5  10 (8.8)   
Serum TGF-β1 (ng/L)) 13.7 (3.7-42.5) 20.1 (3.7-47.8) 13.0 (3.7-37.1) 0.22 
uTGF-β1 (ng/L) 32.5 (19.2-46.6) 33.2 (21.4-45.5) 32.5 (18.2-47.9) 0.64 
uTGF-β1Cr (ng/mmol) 3.7 (1.7-7.5) 4.8 (2.0-11.5) 2.9 (1.2-5.7) <0.001 
Antiretroviral regimens n (%)     
• Zidovudine-based 205 (66.5) 83 (72.8) 122 (62.9)  
• Tenofovir-based 88 (28.6) 26 (22.8) 62 (31.9) 0.09 
• Abacavir-based 11 (3.6) 4 (3.5) 7 (3.6)  
• Protease-inhibitor-based 4 (1.3) 1 (0.9) 3 (1.6)  
HIV+CKD+ (HIV positive patients with CKD); HIV+CKD- (HIV positive patients without CKD);  eGFRCKD-EPI = estimated 
glomerular filtration rate using CKD-EPI equation; eGFRMDRD =estimated glomerular filtration rate using the 4-variable 
MDRD formula; uPCR=urine protein-creatinine ratio; TGF- β1=transforming growth factor-beta1;  uTGF-β1=urinary 
transforming growth factor-beta 1; uTGF-β1Cr=urinary transforming growth factor beta-1 – Creatinine ratio 
TDF=Tenofovir disoproxil fumarate CKD=Chronic kidney disease 





Table 2: Correlations of uTGF-β1Cr with demographic and biochemical parameters 






 Rho p Rho P p-for 
difference 
Rho p 
Age (years) 0.20 0.02 0.09 0.22 0.35 0.19 0.001 
Serum creatinine (µmol/L) -0.35 <0.001 -0.01 0.85 0.003 0.01 0.98 
Serum TGF-β1 (pg/ml) -0.17 0.11 0.03 0.75 0.09 -0.03 0.66 
mABP (mmHg) 0.04 0.62 0.04 0.64 0.99 0.07 0.22 
BMI (kg/m2) 0.02 0.85 -0.14 0.07 0.18 -0.11 0.06 
Waist circumference (cm) -0.03 0.73 -0.07 0.32 0.74 -0.06 0.26 
eGFRMDRD (ml/min/1.73m2) 0.35 <0.001 0.03 0.70 0.01 0.003 0.95 
eGFRCKD-EPI (ml/min/1.73m2) 0.35 <0.001 -0.005 0.99 0.003 -0.02 0.81 
CD4 count (cells/µL) -0.05 0.68 -0.15 0.13 0.40 -0.09 0.20 
uPCR (g/mmol) 0.31 <0.001 0.14 0.05 0.13 0.32 <0.001 
HIV+CKD+= (HIV positive patients with CKD); HIV+CKD-= (HIV positive patients without CKD); TGF-
β1=transforming growth factor-beta-1; mABP=mean arterial blood pressure; eGFR=estimated glomerular 


















Table 3: Linear regression models for uTGF-β1Cr prediction 
 Univariable 
β (95% CI) p-value 
Multivariable 
β (95% CI) p-value 
Study groups   
HIV+CKD- 1 1 
HIV+CKD+ 2.66 (1.85 to 3.47) <0.001 3.97 (2.49 to 5.45) <0.001 
Age (years) 0.04 (0.004 to 0.08) 0.03 0.07 (0.02 to 0.12) 0.01 
Gender   
Female 1 1 
Male -0.98 (-1.13 to 0.94) 0.85 -0.51 (-1.78 to 0.76) 0.43 
mABP (mmHg) 0.04 (0.01 to 0.06) 0.01 0.01 (-0.02 to 0.05) 0.44 
BMI (kg/m2) -0.13 (-0.23 to -0.03) 0.02 0.03 (-0.19 to 0.25) 0.83 
Waist circumference (cm) -0.03 (-0.74 to 0.02) 0.32 -0.05 (-0.15 to 0.06) 0.39 
ARV regimen   
Non TDF-based 1 1 
TDF-based -0.76 (-1.81 to 0.29) 0.15 -2.57 (-6.07to 0.93) 0.15 
CD4 count (cells/µL) -0.01 (-0.01 to 0.006) 0.81 -0.0006 (-0.007 to 0.006) 0.91 
eGFR (CKD-EPI) ml/min/1.73m2 -0.01 (-0.02 to 0.01) 0.24 0.03 (0.01 to 0.05) 0.01 
uPCR (g/mmol) 12.10 (10.58 to 13.62) <0.001 6.62 (2.04 to 11.20) 0.01 
Serum TGF-β1 (pg/ml) 0.002 (-0.001 to 0.002) 0.99 0.0001 (-0.001 to 0.003) 0.93 
HIV+CKD+= HIV positive patients with CKD; HIV+CKD-= HIV positive patients without CKD; ARV=Antiretrovirals; 
mABP=mean arterial blood pressure; TDF=tenofovir disoproxil fumarate; CKD=Chronic kidney disease; 
BMI=Body mass index; eGFR (CKD-EPI) = estimated glomerular filtration rate using the chronic kidney disease 













Table 4: Linear regression models for eGFR prediction 
 Univariate 
β(95% CI) p-value 
Multivariate  
β(95% CI) p-value 
Age (years) -0.87 (-1.16 to -0.57) <0.001 -0.86 (-1.15 to -0.56) <0.001 
Sex 
     Female 
     Male 
 
1 
-0.58 (-8.28 to 7.13) 0.88 
 
1 
4.00 (-3.41 to 11.41) 0.29 
uPCR (g/mmol creatinine) -24.27 (-36.18 to -12.36) <0.001 -29.57 (-42.68 to -16.46) <0.001 
uTGF-β1Cr (ng/mmol) -0.12 (-0.36 to 0.11) 0.31 0.18 (-0.09 to 0.44) 0.19 
Serum TGF-β1 (pg/ml) -0.001 (-0.01 to 0.01) 0.89 -0.001 (-0.01 to 0.01) 0.91 
BMI (kg/m2) 0.24 (-0.54 to 1.02) 0.55 0.09 (-0.64 to 0.82) 0.81 
CD4 count (cells/µL) -0.01 (-0.03 to 0.01) 0.24 -0.01 (-0.03 to 0.01) 0.28 
ARV Regimen 
     Non-TDF regimen 
     TDF regimen 
 
1 
8.88 (1.57 – 16.19) 0.02 
 
1 
6.10 (-1.22 to 13.42) 0.10 
 
The essential findings in Chapter 5 was that of higher uTGF-β1Cr in HIV+CKD+ patients 
compared to HIV+CKD-; progressive reduction in uTGF-β1Cr levels as CKD worsens and that 
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CHAPTER 7: Association of Genetic Polymorphisms of TGF-β1, HMOX1 and 
APOL1 with chronic kidney disease in Nigerian Patients with HIV-related 
nephropathies 
Chapter 7 investigates the association between polymorphisms of TGF-β1, HMOX1 and 
APOL1 polymorphisms with CKD in the adult HIV population in Nigeria, West Africa. 
Following the finding of higher levels of urinary transforming growth factor beta-1 in HIV-
infected patients with CKD, it was pertinent to investigate the association of selected TGF-β1 
SNPs with CKD using the same population in Chapter 5. We went further to determine the 
frequency of APOL1 renal risk variants in a population not previously studied in West Africa 
and analyzed for any possible interaction with TGF-β1 and HMOX1 (which has recently been 
found to be associated with Sickle cell nephropathy in a contiguous population). 
Chapter 7 presents the findings in publication-ready format and is undergoing peer-review 
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Rationale & Objective: We investigated the association of genetic polymorphisms of 
Apolipoprotein-1 (APOL1), transforming growth factor-β1 (TGF-β1)-an important renal pro-
fibrotic cytokine, and Heme oxygenase-1 (HMOX1) with prevalent chronic kidney disease 
(CKD) among adult HIV-infected patients in West Africa. 
Study design: Genetic case-control association study. 
Setting & Participants: Two hundred and seventeen HIV-infected patients with CKD (Group 
A), 595 HIV-infected patients without CKD (Group B), 269 with CKD from other aetiologies 
(Group C) and 114 adults from the normal population (Group D). 
Exposure: rs1800469 (TGF-β1), rs1800470 (TGF-β1), rs121918282 (TGF-β1); rs60910145 
(APOL1 G1), rs73885319 (APOL1 G1), rs71785313 (APOL1 G2) and rs743811 (HMOX1) 
genetic polymorphisms, HIV. 
Outcome: Chronic kidney disease 
Analytical approach: Single Nucleotide Polymorphism (SNP) genotyping of rs1800469 (TGF-
β1), rs1800470 (TGF-β1), rs121918282 (TGF-β1); rs60910145 (APOL1), rs73885319 (APOL1), 
rs71785313 (APOL1) and rs743811 (HMOX1) was undertaken. Hardy-Weinberg equilibrium 
was evaluated for all SNPs and minor allele frequencies (MAF) reported. A case-control 
analysis was performed, and multivariable logistic regression was used to control for 
potential confounders. 
Results: The MAF for rs1800469, rs1800470, rs1800471, rs60910145, rs73885319, 
rs71785313 and rs743811 was 0.25, 0.46, 0.46, 0.44, 0.45, 0.17 and 0.14, respectively. For 
Group A versus B, in the multivariable model, there was reduced odds of CKD with 
rs1800470 [OR 0.44 (95% CI 0.20-0.97)]; increased odds of CKD with APOL1 [2.54 (1.44-
4.51)]; and no association with CKD with rs743811 (0.81 (0.21-3.08). Hypertension had 
increased odds [2.17 (1.35-3.48)]. For Group A versus D, APOL1 was associated with 
prevalent CKD [OR 2.69 (1.23-5.86)]. 
Limitations: The lack of histopathological data for proper categorization of the type of HIV-
related nephropathy. 
Conclusion: APOL1 polymorphisms was highly prevalent in this population and associated 
with increased CKD risk among the adult HIV patients, as did co-morbid hypertension.  While 
TGF-β1 (rs1800470) polymorphisms reduced the risk of CKD in the adult HIV-infected 
population.  
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Rationale & Objective 
Chronic kidney disease (CKD) in the human immunodeficiency virus (HIV) population has 
become an increasingly important cause of morbidity and mortality especially in Sub-
Saharan Africa (SSA), the epicenter of the HIV pandemic. Among the HIV population of SSA, 
estimated to be about 25 million individuals in 2013 (1), about 8% have CKD (2). Multiple 
factors contribute to the development of CKD in the HIV population. These include the 
effects of the virus itself on renal glomerular and tubular epithelial cells; the high prevalence 
and premature onset of cardiovascular risk factors like hypertension, diabetes mellitus and 
dyslipidemia (3); medications (e.g. Tenofovir disoproxil fumarate) used for the treatment of 
HIV and prevention of associated opportunistic infections; and recurrent acute kidney injury 
among HIV patients (4).  
Recent studies have suggested a genetic predisposition to CKD in the HIV population, 
especially in SSA. A retrospective cohort study conducted in the United Kingdom that 
comprised HIV patients of different African ethnicities documented a 6-times increased risk 
of progression to end-stage renal disease (ESRD) in HIV-infected individuals of West African 
origin compared to those of East African origin (5). In the same study, black individuals of 
Caribbean origin (who have a shared ancestry with those of the West African sub-region) 
had a 5-time increased risk of progression to ESRD compared to those of East African origin. 
This finding corroborated a meta-analysis finding of the highest prevalence of CKD among 
HIV patients in the West African sub-region compared to other regions in SSA (2). Regardless 
of genetic polymorphisms of apolipoprotein L1 (APOL1) that have been clearly documented 
as an important genetic risk factor for CKD of various aetiologies including HIV (6-8), there is 
need to identify other genetic risk factors for CKD in the HIV population (9).  
Transforming growth factor beta-1 (TGF-β1) is a 25KDa cytokine that plays a central role in 
extracellular matrix expansion and renal fibrosis (10).  





Genetic regulation of its expression may be an important factor for CKD occurrence and 
progression in the HIV population (11, 12). Other genetic factors like heme oxygenase 
(HMOX1) polymorphisms implicated in sickle cell nephropathy (13) may also play a role in 
HIV-related nephropathy and the occurrence of microalbuminuria (14). In this study, we 
investigate the association of TGF-β1, APOL1 and HMOX1 genetic polymorphisms with 
prevalent CKD in the HIV population of West Africa. 
METHODS 
Ethical approval  
The study was approved by the University of Cape Town, Faculty of Health Sciences Human 
Research Ethics Committee (HREC REF: 733/2016), Cape Town, South Africa and the 
University of Uyo Teaching Hospital Research Ethics Committee 
(UUTH/AD/S/96/VOL.XIX/15). All patients signed consent forms in accordance with the 
declaration of Helsinki. All data was anonymized to ensure confidentiality.  
Study Participants  
A total of 1195 adults [217 HIV-infected adults with CKD (Group A); 595 HIV-infected without 
CKD (Group B); 269 with CKD from other aetiologies (Group C); and 114 from the general 
population without CKD and HIV (Group D)] were recruited prospectively. Socio-
demographic (age, gender, ethnicity), anthropometric (height, weight, body mass index 
[BMI], waist circumference, hip circumference, waist-hip ratio), family or personal history of 
diabetes mellitus and hypertension were collected. Systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) were measured using standard techniques. Mean arterial 
blood pressure (mABP) was calculated using the equation [DBP + (SBP-DBP)/3]. Other clinical 
variables collected include CD4 count at initiation of care and at the time of sample 
collection; viral load at initiation of care and at the time of sample collection; hepatitis B 
surface antigen and hepatitis C status; and the antiretroviral (ARV) regimen administered to 
the HIV-infected patient. All participants in the main subject group (Group A) were HIV-
infected, confirmed using western blot assays and on treatment using defined antiretroviral 
(ARV) regimens for at least 6 months and had CKD.  





Renal function measurement 
Serum creatinine was measured using isotope dilution mass spectrophotometry, IDMS-
traceable methods. The glomerular filtration rate was estimated using the 4-variable 
modification of diet in renal disease (MDRD) (15) and chronic kidney disease epidemiology 
collaboration (CKD-EPI) (16) equations. The CKD-EPI and MDRD equations without the race 
factor was utilized for estimating GFR in this study given that recent studies (17-19) have 
suggested that the inclusion of race may generate less precise estimates in the black 
population. Urinary protein was measured using turbidometric method employing 
trichloroacetic acid (Merck, USA) while urinary creatinine was measured using RANDOX 
creatinine kit (RANDOX, UK). Urine protein-creatinine ratio (uPCR) was calculated in g/mmol 
creatinine. Chronic Kidney Disease was defined as two consecutive values of estimated 
glomerular filtration rate (eGFR) <60mL/min/1.73m2 and/or urine protein-creatinine ratio ≥ 
0.05g/mmol recorded in a period at least 3 months apart (20).  
Molecular methods 
DNA was extracted from peripheral blood using manufacturer’s instructions (Quick-DNATM 
Miniprep plus kit, Zymo Research, California, USA). Targeted SNPs in TGF-β1, APOL1 and 
HMOX1 genes—SNP genotyping of rs1800469 (TGF-β1), rs1800470 (TGF-β1), rs1800471 
(TGF-β1), rs121918282 (TGF-β1); rs60910145 (APOL1 G1), rs73885319 (APOL1 G1), 
rs71785313 (APOL1 G2) and rs743811 (HMOX1) was undertaken. The PCR protocols were 
performed on the Bio-Rad CFX96 real time PCR system (Bio-Rad Laboratories, Hercules, CA, 
USA) by using TaqMan assay, fragment analyses using ABI prism and iPLEX GoldSequenom 
Mass Genotyping (Inqaba biotech, Pretoria South Africa). Thereafter, Direct Cycle 
Sequencing using the ABI Prism 3130 xl was performed on a subset (10%) of the samples for 
validation. 
Statistical Analysis 
Data analysis was performed using Stata 15.1 (StataCorp Inc., College Station, TX, USA). 
Descriptive analyses were performed, and data presented as frequencies (and percentages), 
means (± standard deviation), or medians [25th-75th percentiles] as appropriate.  





Pearson’s Chi-square was used to compare proportions across the four study groups while 
ANOVA was used to compare means for quantitative variables and the Kruskal-Wallis test 
for skewed variables. The Bonferroni correction was used with the ANOVA for pairwise 
comparison of the means. A χ2 test with one degree of freedom was used to test SNPs data 
for any departure from Hardy-Weinberg equilibrium (HWE). A case-control analysis was 
performed using recessive, dominant and additive models to assess for association between 
polymorphism and prevalent CKD by fitting univariable (unadjusted) logistic regression 
models with the SNPs being the independent variables. The Cochran-Armitage trend test 
was employed to further analyze for genotypic association in the additive model. Analysis 
involving group C was performed with or without individuals with diabetes mellitus. 
Multivariable logistic regression models were used to identify independent association of 
genetic variables with prevalent CKD after adjusting for the effect of known possible clinical 
confounders. For the APOL1 SNPs, the joint effects of the G1 and G2 SNPs were combined 
for the multivariable models. Those with G1 and G2 homozygotes and G1/G2 compound 
heterozygotes were deemed to have 2 risk alleles; the G1/G0 and G2/G0 heterozygotes had 
1 risk allele while those with G0/G0 were coded to have zero risk allele. The multivariable 
logistic regression models were fitted with APOL1 G1/G2 in recessive model. p-values less 
than 0.05 were deemed statistically significant.  
RESULTS 
Study Population 
Most (84.7%) of the participants were of similar geographic (bordering the Atlantic Ocean 
along the west coast of Africa) and linguistic origin. This includes the Ibibio (60.7%), Annang 
(17.8%), Efik/Ekoi (3.0%), and Oron (3.2%). Other ethnic groups were Ibo (7.3%) and Yoruba 
(4.8%). Table 1 summarizes the sociodemographic and clinical characteristics of the study 
participants. Individuals in group C were older, had fewer females and higher mABP 
compared with the other groups. Group C individuals also had higher waist circumference 
and greater proportion of obese individuals.  
 





The aetiology of CKD among group C individuals included hypertension (35.2%), diabetes 
mellitus (27.8%), chronic glomerulonephritis (15.9%), obstructive uropathy (4.4%), polycystic 
kidney disease (1.5%), sickle cell nephropathy (0.4%) and indeterminate (12.2%). There was 
no significant difference in CD4 count, viral load, proportion using tenofovir disoproxil 
fumarate (TDF)-based regimen, hepatitis B and C co-infection and duration on antiretrovirals 
(ARVs) between group A and B. The HIV positive participants had higher female 
preponderance than the other groups. Within group A, the proportion of individuals with 
the various CKD stages, 1 – 5 respectively was 21.5%, 21.1%, 35.3%, 5.9% and 16.2% 
respectively. For group C, it was 0.4%, 2.6%, 10.7%, 16.3% and 70.0% for stages 1-5 
respectively.  
 
Comparison of MAF with the 1000 genomes project 
Table 2 summarizes the minor allele frequencies (MAF) for the studied SNPs and compares 
these with that obtained for the African, African American and European populations from 
the 1000 genomes project. The MAF for the APOL1 SNPs were twice the proportion found in 
other African populations and significantly higher compared to the African American and 
European populations. The MAF for rs71785313 (APOL1 G2 SNP) of our cohort was similar to 
the African and African American values but significantly different from the European values. 
The MAF for the TGF-β1 SNPs (rs1800470 and rs1800471) and HMOX1 were also 
comparable to that found in other African and African American populations but different 
from the European population. rs121918282 was monomorphic and not used for 
subsequent analyses.  
Genetic associations with CKD between cases and controls 
The p-values for the genotypic trend test comparing groups A and B for rs1800469 (TGF-β1), 
rs1800470 (TGF-β1), rs1800471 (TGF-β1), rs60910145 (APOL1), rs73885319 (APOL1), 
rs71785313 (APOL1), rs743811 (HMOX1) were  0.64, 0.04, 0.17, <0.001, <0.001, 0.87 and 
0.96, respectively.  





The p-values for the genotypic trend test comparing groups A to D for rs1800469, 
rs1800470, rs1800471, rs60910145, rs73885319, rs71785313, rs743811 were 0.22, 0.45, 
0.18, 0.001, 0.001, 0.70, and 0.66, respectively.  
A summary of the odds ratios (and 95% confidence intervals) comparing groups A to B; A to 
D and C to D using the dominant, recessive and additive models is given on Table 3. 
rs1800470 (TGF-β1), in the dominant model, was significantly associated with prevalent CKD 
when groups A and B were compared. There was increasing risk of CKD as the number of 
renal risk alleles increased for the APOL1 G1 SNPs but not for the APOL1 G2 SNP. In the 
recessive model, the APOL1 G1 SNPs consistently showed increased risk for CKD across 
comparison categories.  
Multivariable models 
Multivariable logistic regression models for A versus B, A versus D and C versus D (Table 4) 
showed independent association between APOL1 and CKD in the HIV population. This 
relationship persisted when the HIV-CKD group was compared to the general population. 
There was a 2.5 times increased odds of CKD among HIV patients with the APOL1 genetic 
risk even after adjustment for the effect of other potential confounders. There was 
statistically significant reduction in the odds of having CKD with the TGF-β1 SNP, rs1800470, 
suggesting a possible protective effect. Traditional CKD risk factors like hypertension also 
significantly predicted CKD in the HIV population (Table 4).  
 
DISCUSSION 
This analysis is one of the few large studies investigating genetic risk factors for CKD in West 
Africa. Overall, there was a high prevalence of hypertension and other cardiovascular risk 
factors among the study participants. All the SNPs analyzed had MAF significantly different 
from the available European data.  
 





For TGF-β1, the MAF of rs1800469 and rs1800471 were lower while rs1800470 was higher in 
our population compared to the European population. The MAF for HMOX1 was also higher 
in the European data compared to that found in our population. The MAF for all the SNPs 
were similar in our data compared to the African American data except for the APOL1 G1 
SNPs which were about double the frequency in the African American population. The MAF 
for the APOL1 G2 SNP was like that found among the African Americans. Both APOL1 G1 
SNPs were associated with significantly higher odds of CKD in the HIV population and when 
compared to non-HIV controls. The APOL1 G2 SNPs did not show significant difference 
between the HIV patients with CKD compared with the other control groups. In 
multivariable models, rs1800470 (TGF-β1) was associated with a 56% reduction in CKD odds 
among the HIV population while the combined APOL1 gene, in the recessive model, had 
about 2.5 times increased odds of CKD.  
Since the discovery of APOL1 genetic odds among the African American population, there 
has been keen interest in determining the frequency and contribution of the APOL1 to the 
increasing CKD burden in SSA. The findings have been quite variable, ranging from the 
complete absence of APOL1 odds variants in Ethiopian populations (21) to intermediate 
APOL1 prevalence in other Eastern African communities (22) and then to the very high 
prevalence in West Africa (23, 24). In the Ethiopian study, none of the HIV patients had the 
APOL1 G1 SNP while the APOL1 G2 SNP was found in only 2 patients in the heterozygous 
state out of 338 patients. The frequency of the APOL1 renal odds variants was 9-11% in a 
study from East Africa (22) and this value corresponds closely to many other studies in the 
region. In West Africa, some studies have documented one of the highest APOL1 renal odds 
variant frequencies and this corresponds to the highest CKD prevalence in Sub-Saharan 
Africa (25). Among the Yoruba ethnic group (24), the MAF for rs60910145 (G1), rs73885319 
(G1) and rs71785313 (G2) was 40.6%, 35.8% and 10.5% respectively compared to the 
current study which was 44.0%, 45.3% and 16.8% (p=0.39, 0.02 and 0.04 respectively) 
indicating a higher frequency of the APOL1 odds alleles in this population. This study was 
undertaken among the Niger-Congo tribes living next to the Atlantic Ocean along the west 
coast of Africa.  





This region still bears the relics of the trans-Atlantic slave trade and ports and may well be 
responsible for a good proportion of the APOL1 bearing individuals in the Caribbean Islands 
and North America. These regions also have some of the highest proportions of CKD patients 
among the HIV population (2, 5).  
We found a 2.5 times increased odds of CKD among our HIV patients with APOL1 genetic 
odds which is a much smaller effect size compared with that found in studies in South Africa 
(7) (89 times increased odds) or that found among African Americans (26) (29 times 
increased odds). This large disparity in effect size may be due to the lack of histopathologic 
data and therefore the heterogenous nature of the HIV-CKD group in this study.  Chronic 
kidney disease in the HIV population may be due to HIV-associated nephropathy (HIVAN), 
HIV immune complex kidney disease (HIVICK), HIV thrombotic microangiopathy (HIVTMA), 
CKD from hypertension or diabetes mellitus with co-existent HIV infection or CKD arising 
from tenofovir-induced renal injury. Renal histopathologic data would have made it possible 
to compare APOL1-driven odds for CKD in biopsy proven HIVAN in our population. HIVTMA 
and HIVICK do not appear to be associated with APOL1 genetic odds (7, 27) and therefore 
their presence in our sample may have attenuated the APOL1 effect size. Considering the 
high proportion of HIV patients with hypertension in our sample, there is a possibility that a 
good proportion of these patients have hypertension-attributable CKD with co-existent HIV 
disease. This may also dilute the effect of APOL1. Renal histopathologic data in the HIV 
population in Africa is largely unavailable.  
Even in patients with biopsy proven HIVAN, 20-30% do not carry the high odds variants of 
APOL1 and as much as 8% carry no APOL1 odds variant (7, 28) suggesting other possible 
genetic or environmental factors.  Another notable finding in this study, was the protective 
effect of rs1800470 on CKD. However, previous studies have reported conflicting results 
relating to the association between TGF-β SNPs and CKD. An increased odds was noted with 
rs1800471 in a Caucasian population (29) while a recent meta-analysis (30) has shown 
increased CKD odds (in the non-HIV population) among Asians and a CKD-protective effect 
of another TGF-β1.  





Therefore, the effect of TGF-β1 polymorphisms on CKD remains inconclusive. 
HMOX1 polymorphisms, on the other hand, was not associated with CKD odds regardless of 
genetic model used, and it appears its relationship with CKD may be limited to sickle cell 
nephropathy (13, 31). Therefore, the search for other potential genetic factors predisposing 
to CKD in the HIV sub-population should continue while not taking attention from the 
multiple environmental factors that promote the development of CKD among individuals 
with APOL1 genetic odds variants. 
While genetic odds factors for CKD in the HIV population are complex and generally non-
modifiable, environmental odds factors are modifiable and may serve as an avenue for the 
reduction of CKD odds in the HIV population of Sub-Saharan Africa. Combating the high 
prevalence of hypertension, diabetes mellitus, obesity and dyslipidemia (3, 32, 33) in the 
relatively young population of patients with HIV in Africa remains the most viable option for 
controlling CKD odds apart from the use of combined antiretroviral medications.  
The major limitation of this study is the lack of histopathological data. This limitation is 
further enhanced by the lack of local data on the distribution and frequency of different 
glomerular and tubular lesions among the HIV patients with CKD. This has highlighted the 
need for large renal clinicopathologic studies among the HIV-CKD population in this region. 
 
CONCLUSION 
APOL1 is associated with increased odds of CKD in the adult HIV population of West Africa 
while at least one SNP of TGF-β1 may be protective against CKD. Although the role of 
genetics in the initiation and progression of CKD in the HIV population of West Africa is 
increasingly becoming evident, it is important to also pay close attention to the threat of 
non-communicable disease in the HIV population where interventions may serve as means 
of reducing the proportion who progress to end-stage kidney disease. 
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Table 1: Sociodemographic and clinical characteristics of study participants 















Age (years) 42.3±12.9 42.2±10.9 39.2±10.8 50.6±14.6 39.7±13.5 <0.001 
Female gender n (%) 750 (62.7) 146 (67.3) 442 (74.3) 96 (35.7) 66 (57.9) <0.001 
SBP (mmHg) 132.8±27.0 136.4±29.0 126.6±23.7 147.3±29.8 126.3±18.7 <0.001 
DBP (mmHg) 80.9±15.8 83.4±17.5 77.6±13.9 87.3±17.5 79.2±12.5 <0.001 
mABP (mmHg) 98.2±18.4 101.1±20.3 93.9±16.3 107.3±19.9 95.0±13.1 <0.001 
Hypertension n (%) 559 (46.8) 108 (49.8) 176 (29.6) 237 (88.1) 38 (33.3) <0.001 
Diabetes Mellitus n (%) 112 (9.4) 15 (6.9) 13 (2.2) 79 (29.4) 5 (4.5) <0.001 
BMI (kg/m2) 24.2±5.2 23.6±5.5 23.6±4.8 25.8±5.0 25.3±6.0 <0.001 
Obesity n (%) 143 (12.0) 22 (10.1) 56 (9.4) 40 (14.9) 25 (21.9) 0.001 
Waist circumference (cm) 84.3±21.9 82.4±11.4 83.1±28.4 88.3±13.2 84.6±12.2 0.01 
Hip circumference (cm) 93.8±10.8 91.8±9.7 93.7±9.5 94.7±13.5 96.5±12.1 0.002 
Waist-hip ratio 0.90±0.23 0.89±0.08 0.89±0.31 0.95±0.10 0.88±0.07 0.003 
Family history of HTN n 
(%) 
346 (28.9) 45 (20.7) 123 (20.7) 133 (49.4) 45 (39.5) <0.001 
Family history of DM n (%) 166 (13.9) 24 (11.1) 59 (9.9) 63 (23.4) 20 (17.5) <0.001 
uPCR (g/mmol) 0.04 (0.02-0.07) 0.14 (0.05-0.27) 0.03 (0.02-0.05) 0.12 (0.06-0.53) 0.03 (0.02-0.04) 0.002 





eGFRMDRD (ml/min/1.73m2) 64.8 (63.6-83.9) 46.9 (30.3-70.8) 74.5 (61.7-93.2) 9.7 (4.8-21.3) 76.2 (63.6-89.0) <0.001 
eGFRCKD-EPI (ml/min) 71.1 (34.0-96.2) 49.6 (31.1-78.7) 84.4 (70.3-105.4) 8.3 (5.4-18.2) 88.7 (73.3-106.0) <0.001 
CD4 count (cells/uL) 283 (157-473) 273 (148-425) 291 (160-492) - - 0.54 
Viral load (log10) 2.2 (1.3-3.8) 2.4 (1.4-4.3) 2.2 (1.3-3.7) - - 0.53 
TDF-regimen n (%) 223 (18.7) 41 (18.9) 182 (30.6) - - 0.001 
HBV co-infection n (%) 16 (1.9) 4 (1.8) 12 (2.0) - - 0.88 
HCV co-infection n (%) 2 (0.2) 1 (0.5) 1 (0.2) - - 0.46 
Duration on ARVs (years) 5.0 (2.0-9.0) 5.0 (2.0-9.0) 5.0 (2.0-9.0) - - 0.63 
HIV=Human immunodeficiency virus; CKD=Chronic kidney disease; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; mABP=mean arterial blood pressure; BMI=Body mass index; 
HTN=hypertension; DM=diabetes mellitus; uPCR=urine protein-creatinine ratio; eGFRMDRD=estimated glomerular filtration rate using 4-variable modification of diet in renal disease 














Table 2: Comparison of minor and major allele frequencies of TGF-β1, APOL1, HMOX1 between the 1000 Genomes Project 
TGF-β1=transforming growth factor beta-1 gene; APOL1=apolipoprotein-1 gene; HMOX1=heme oxygenase-1 gene; Chr=chromosome. 
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Table 3: SNP associations with CKD among HIV+/CKD- (control) and HIV+/CKD+ (cases) 



















TGF-β1 rs1800469 19:41354391 Major G 0.748 (1730) 0.782 (1034) 0.795 (97) 0.688 (692) 0.04 0.30 0.003   
 Minor A 0.252 (582) 0.218 (288) 0.205 (25) 0.312 (314)    
 
rs1800470 19:41353016 Major A 0.542 (1147) 0.586 (775) 0.623 (76) 0.618 (622) 0.06 0.17 0.002 
  
 Minor G 0.458 (969) 0.414 (547) 0.377 (46) 0.382 (384)    
  rs1800471 19:41352971 Major C 0.954 (2153) 0.943 (1247) 0.934 (114) 0.929 (935) 0.16 0.33 0.005   
 Minor G 0.046 (103) 0.057 (75) 0.066 (8) 0.071 (71)    
 
rs121918282 11:123653773 Major A 1.00 (1223) 1.00 (15304) - - - - - 
  
 Minor - - - - -    
APOL1 rs60910145 22:36265988 Major T 0.560 (1193) 0.741 (980) 0.779 (95) 1.000 (1006) <0.001 <0.001 <0.001 
  
 Minor G 0.440 (939) 0.259 (342) 0.221 (27) -    
 
rs73885319 22:36265860 Major A 0.547 (1151) 0.741 (979) 0.779 (95) 1.000 (1006) <0.001 <0.001 <0.001 
  




Major TTATAA 0.832 (1320) 0.855 (1004) 0.891 (98) 1.000 (1006) 0.13 0.13 <0.001 
   Minor  0.168 (266) 0.155 (171) 0.119 (12) -    
HMOX1 rs743811 22:35396981 Major T 0.856 (1879) 0.863 (1141) 0.844 (103) 0.747 (751) 0.59 0.74 <0.001 
  





Gene SNP HWE Association 
mode* 
Unadjusted OR (95% CI), p 
(A versus B) 
Unadjusted OR (95% CI), p  
(A versus D) 
Unadjusted OR (95% CI), p 
(C versus D) 
TGF-β1 rs1800469 0.73 Dominant 0.94 (0.69-1.30) 0.73 1.33 (0.81-2.19) 0.26 1.18 (0.72-1.91) 0.51 
   Recessive 0.81 (0.45-1.48) 0.50 1.79 (0.58-5.54) 0.31 2.08 (0.70-6.23) 0.19 
   Additive 0.93 (0.73-1.19) 0.58 1.31 (0.87-1.98) 0.19 1.23 (0.84-1.82) 0.29 
       
TGF-β1 rs1800470 0.61 Dominant 0.69 (0.48-0.98) 0.04 1.20 (0.71-2.01) 0.50 1.33 (0.80-2.21) 0.58 
   Recessive 0.77 (0.51-1.16) 0.22 1.20 (0.62-2.32) 0.58 1.20 (0.63-2.28) 0.27 
   Additive 0.78 (0.62-0.99) 0.04 1.14 (0.80-1.63) 0.45 1.20 (0.84-1.71) 0.30 
       
TGF-β1 rs1800471 0.81 Dominant 1.45 (0.85-2.45) 0.17 1.81 (0.75=4.36) 0.19 1.50 (0.63-3.58) 0.36 
   Recessiveµ - - - 
   Additive 1.40 (0.83-2.34) 0.20 1.81 (0.75-4.36) 0.19 1.52 (0.65-3.56) 0.33 
       
APOL1 rs60910145 0.08 Dominant 1.95 (1.33-2.85) 0.001 2.09 (1.23-3.57) 0.007 1.25 (0.77-2.05) 0.37 
   Recessive 1.72 (1.17-2.51) 0.006 2.71 (1.38-5.38) 0.004 2.17 (1.11-4.25) 0.02 
   Additive 1.56 (1.24-1.97) <0.001 1.89 (1.31-2.73) 0.001 1.37 (0.98-1.92) 0.06 
       
APOL1 rs73885319 0.61 Dominant 2.01 (1.36-2.97) <0.001 2.08 (1.20-3.58) 0.009 1.16 (0.70-1.92) 0.55 
   Recessive 1.70 (1.16-2.49) 0.006 2.74 (1.39-5.39) 0.004 2.19 (1.12-4.30) 0.02 
   Additive 1.58 (1.25-2.00) <0.001 1.91 (1.32-2.77) 0.001 1.34 (0.95-1.87) 0.09 
       
APOL1 rs71785313 0.09 Dominant 0.96 (0.65-1.43) 0.86 1.11 (0.61-2.01) 0.74 1.33 (0.74-2.40) 0.34 
   Recessive 1.03 (0.46-2.28) 0.95 1.41 (0.37=5.37) 0.61 2.10 (0.59-7.53) 0.26 
   Additive 0.98 (0.71-1.34) 0.91 1.12 (0.69-1.82) 0.65 1.33 (0.84-2.13) 0.22 
       
HMOX1 rs743811 0.08 Dominant 1.03 (0.71-1.48) 0.89 1.14 (0.66-1.97) 0.65 0.75 (0.43-1.31) 0.32 
   Recessive 0.63 (0.21-1.90) 0.41 0.97 (0.18-5.44) 0.98 0.80 (0.14-4.45) 0.80 
   Additive 0.98 (0.71-1.34) 0.89 1.11 (0.68-1.81) 0.69 0.48 (0.43-1.28) 0.34 
*For the additive model, the first row represents the heterozygous state while the second row represents the homozygous state for the minor allele. The homozygous 
state of the major allele is the reference group. 





TGF-β1=Transforming growth factor beta-1 gene; APOL1=Apolipoprotein-1 gene; HMOX1=Heme oxygenase 1 gene; SNP=Single nucleotide polymorphism; OR=Odds 
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Table 4: Multivariable logistic regression models controlling for environmental factors 
 Group A versus B Group A versus D  Group C versus D  
 Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value 





GG 1 1 1 
GA 1.35 (0.79-2.29) 0.27 1.20 (0.53-2.68) 0.66 0.59 (0.20-1.70) 0.33 
AA 1.32 (0.43-4.01) 0.63 1.64 (0.28-963) 0.58 1.67 (0.23-11.87) 0.61 
rs1800470    
AA 1 1 1 
GA 0.59 (0.34-1.03) 0.06 1.08 (0.49-2.41) 0.84 2.06 (0.74-5.71) 0.17 
GG 0.44 (0.20-0.97) 0.04 0.89 (0.27-2.90) 0.35 2.14 (0.46-9.89) 0.33 
rs1800471    
CC 1 1 1 
CG 1.45 (0.68-3.08) 0.34 1.80 (0.52-6.24) 0.35 0.54 (0.11-2.61) 0.45 
GG - - - 
rs743811    
TT 1 1 1 
TC 1.30 (0.81-2.08) 0.28 1.80 (0.84-3.87) 0.13 0.89 (0.35-2.27) 0.80 
CC 0.81 (0.21-3.08) 0.76 2.29 (0.21-25.07) 0.50 2.56 (0.09-75.71) 0.59 
Age (years) 1.02 (0.99-1.04) 0.17 1.01 (0.98-1.05) 0.38 1.04 (1.01-1.07) 0.01 
APOL1 (recessive) 2.54 (1.44-4.51) 0.001 2.69 (1.23-5.86) 0.01 1.13 (0.46-2.72) 0.79 
Sex     
    Female 1 1 1 
    Male 1.24 (0.78-1.99) 0.36 0.48 (0.23-0.96) 0.04 1.93 (0.86-4.36) 0.11 
Hypertension 2.17 (1.35-3.48) 0.001 1.79 (0.83-3.86) 0.14 12.63 (5.41-29.53) <0.001 
Diabetes Mellitus 2.48 (0.90-6.78) 0.08 1.19 (0.22-6.25) 0.83 5.68 (1.14-28.26) 0.03 
Waist circumference (cm) 0.99 (0.97-1.01) 0.61 1.02 (0.97-1.07) 0.34 0.98 (0.94-1.03) 0.45 
BMI (Kg/m2) 0.98 (0.92-1.05) 0.56 0.91 (0.82-1.01) 0.07 1.03 (0.93-1.14) 0.51 
BMI=Body mass index 
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Gene SNP Association 
mode 
Unadjusted OR (95% CI), p 
(C versus D) 
    
APOL1 rs60910145 Dominant 1.17 (0.69-1.97) 0.56 
  Recessive 2.65 (1.33-5.30) 0.006 
  Additive 1.40 (0.99-1.98) 0.05 
    
APOL1 rs73885319 Dominant 1.08 (0.64-1.83) 0.78 
  Recessive 2.71 (1.36-5.40) 0.005 
  Additive 1.37 (0.97-1.94) 0.07 
    
APOL1 rs71785313 Dominant 1.26 (0.68-2.34) 0.46 
  Recessive 2.03 (0.54-7.64) 0.29 
  Additive 1.28 (0.79-2.09) 0.32 
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CHAPTER 8: SYNTHESIS-CONCLUSION AND RECOMMENDATION  
Approximately 36.7 million people live with HIV infection worldwide with about two-third of 
them living in sub-Saharan Africa (118, 119). Access to ARVs in sub-Saharan Africa is still 
below desired levels with about 64% of those in needs, receiving such treatment 120. 
However, there has been significant improvement in the life expectancy of HIV-positive 
individuals for those who have access to treatment increasing the likelihood of the 
development of NCDs. These NCDs (including hypertension, diabetes mellitus, obesity and 
dyslipidaemia) make the occurrence of CKD more likely, apart from the direct effect of HIV 
on renal tissues. If the ambitious 90-90-90 target (121) of diagnosing 90% of HIV infections, 
getting 90% of HIV patients on treatment and achieving viral suppression in 90% of those on 
treatment is successful or nearly so, then we should envisage an upsurge in the prevalence 
of NCDs in the HIV population. Increasingly, it appears that the overall success and long-
term sustainability of the various HIV care programs soon will be dependent on the systems 
created now for dealing with NCDs in the HIV population. Akin to this will be the need to set 
up systems to identify and mitigate the effects of genetic predisposition to NCDs (including 
CKD) in the HIV population. 
The spectrum of kidney disease in the HIV population ranges from AKI, through CKD to 
opportunistic infections of the kidney and infiltrative lesions of the kidney like lymphoma 
and Kaposi sarcoma (122). AKI could result from prerenal azotemia, acute tubular necrosis, 
ARV-associated acute kidney injury and acute tubulointerstitial nephropathy from immune 
reconstitution syndrome.  





Other causes of AKI among HIV-positive patients include the HIV-immune complex kidney 
disease, thrombotic microangiopathies and bacterial urinary tract infection. Opportunistic 
infections of the kidneys including viral, fungal and mycobacterial infections also may cause 
significant morbidity in this patient group. CKD could occur from HIVAN, HIVICK, ARV-
associated CKD, chronic tubulointerstitial nephropathy and crystal nephropathy. Ultimately, 
if not diagnosed early and appropriate treatment instituted, all forms of kidney disease in 
this population will result in CKD and possible progression to ESRD if the HIV-positive patient 
lives long enough.  
The overarching aim of this work was to document the prevalence of CKD in the global adult 
HIV population and compare the prevalence across different WHO regions; determine the 
prevalence of CKD and other NCDs in the extreme southern Nigeria which has a high HIV 
prevalence; investigate the association between urinary TGF-β1 and prevalent CKD in the 
adult HIV population and investigate any association between TGF-β1, APOL1 and HMOX1 
polymorphisms with CKD in the HIV population. Using meta-analytic methods, the 
prevalence of CKD among HIV patients across the WHO regions were synthesized and 
comparisons made. In sub-Saharan Africa, the epicenter of the HIV pandemic, comparison 
was made across the African Union sub-regions in order to establish a geographical 
differentia in CKD-HIV prevalence. It was then necessary to determine the prevalence of CKD 
in the adult HIV population from which the genetic and urinary TGF-β1 samples will be 
obtained. 
 





 The overall prevalence of CKD in the global HIV population was 4.8-12.3% depending on the 
GFR estimating equation used [6.4% (95%CI 5.2–7.7%) with MDRD, 4.8% (95%CI 2.9–7.1%) 
with CKD-EPI and 12.3% (95%CI 8.4–16.7%) with Cockcroft–Gault]. Of all the WHO regions, 
the highest prevalence was found in sub-Saharan Africa while within Africa, the sub-region 
with the highest prevalence was West Africa. This finding may not be unconnected with the 
genetic epidemiology of APOL1 which has the highest worldwide prevalence of APOL1 
genetic risk in West Africa and high occurrence in the Caribbean islands and among African 
Americans, both being of African ancestry with forefathers having been part of the 
transatlantic slave route (112, 123).  This assertion is corroborated by a recent study (124) 
which followed up HIV-positive individuals of West African, East African and Caribbean origin 
living in the United Kingdom which showed significantly increased rate of progression to CKD 
in individuals of West African and Caribbean origin compared to those of East African origin. 
This finding has far-reaching consequences for ESRD patients and their relatives living in 
West Africa because the predominant source of kidneys in Nigeria for transplantation is 
from living-related donors. There may be a high risk of development of APOL1-associated 
FSGS in the related donor.  
The wide disparity in CKD prevalence noted across the three GFR estimating equations 
suggests significant lack of concordance in the eGFR derived from existing serum creatinine-
based equations in the black HIV population. This disparity has been noted by other studies 
among HIV-positive patients in Africa (125) and among African Americans (126) and is made 
more complicated by the choice of including (or not) the race factor in the equation.  





An effort to determine the most accurate equation in this population was undertaken in 
Kenya using measured GFR from iohexol clearance (127) indicated the CKD-EPI equation 
(without the race factor) as the most accurate creatinine-based equation. This study 
however had certain limitations including a small sample size (99 individuals) and lack of 
generalizability because the participants were mostly in early CKD with a very small 
proportion with GFR less than 60ml/min/1.73m2 and all patients were ARV-naïve. Therefore, 
this signals a need to develop new equations or modify existing serum creatinine-based 
equations for the black HIV population which will be accurate enough for the purposes of 
dosing of ARV (and other medications) and monitoring of renal function in the long-term. 
In West Africa, the prevalence of CKD in the HIV population using the most conservative of 
the three studied equations, the CKD-EPI equation, was 9.2% (4.8-14.8%) from our summary 
estimates. We recorded a prevalence of 13.4% using the same equation in the population of 
Nigeria’s Niger-Delta where the samples for this work was collected which is within 95% 
confidence interval of our summary estimate. This is a high prevalence, considering that 
prevalence was based on eGFR<60ml/min/1.73m2 without taking into cognizance those with 
persistent proteinuria. This means that at least 455,600 of the 3.4 million HIV-positive 
patients in Nigeria (128) are in at least stage 3 CKD. This is a grim picture in a country with a 
dysfunctional health system where most patients pay out-of-pocket for treatment. It is 
therefore necessary to incorporate CKD screening and treatment programs into HIV/AIDS 
program for the purpose of early identification and appropriate management of CKD and its 
traditional risk factors (which have high prevalence in this patient group as documented in 
this work).  





We documented a high prevalence of hypertension [26.7% (95% CI 25.5% to 28.0%)], 
diabetes mellitus [5.6% (95% CI 4.5% to 6.7%)], and dyslipidemia [29.1% (95% CI 26.1% 
to 32.1%)], among our HIV-positive patients especially considering the relatively low 
average age (34.3 ± 9.9 years).  
The need for early identification of CKD in the HIV population led to the investigation of the 
utility of urinary TGF-β1 as a possible biomarker for CKD progression. We considered that for 
a biomarker to be useful in this clime it should have the following characteristics: 
 
1. Have great discriminatory ability to detect CKD using one sample and not repeated 
samples as currently obtained with urine albumin-creatinine ratio. There is usually 
great tendency to have loss to follow up in NCDs clinics in resource-poor settings.  
2. Be affordable for people living in resource-poor communities or at least cheap 
enough to be integrated into screening programs in HIV clinics. 
3. Should not require expensive equipment for assay. 
4. Assay should be reproducible. 
5. Sample used for assay should be easy to collect, preferably by the patient. 
Using urine samples will ensure easy collection of samples, but this has already been 
achieved with the widespread use of urine albumin-creatinine ratio for early detection of 
CKD. TGF-β1 ELISA assay is reproducible using standard techniques but the kits are not 
cheaper than urine albumin-creatinine ratio and ELISA equipment may be beyond the reach  





of many laboratories in low income countries of Sub-Saharan Africa therefore potentially 
limiting its widespread use. Also, there is need to do proper cohort studies with follow up 
periods long enough to determine if high urinary TGF-β1 levels at initiation of care is a good 
predictor of progression to CKD in the HIV cohort. Our finding from this cross-sectional study 
showed higher urinary TGF-β1 levels in patients with early CKD with waning levels as CKD 
stage worsened. It is possible that urinary TGF-β1 will be at least, a component of a battery 
of biomarkers used for the non-invasive prediction of CKD progression in the HIV population 
in the near future. We also had theorized that polymorphisms of this cytokine gene may be 
involved in the pathogenesis of CKD in the HIV population similar to that documented in 
ESRD caused by diabetes and chronic glomerulonephritis (129). 
This work is, to the best of our knowledge, the first investigation of TGF-β1 SNPs and their 
association with CKD in Sub-Saharan Africa. There may be a protective association between 
rs1800470 polymorphisms and CKD in the HIV population even at the multivariable 
regression level. There is a possibility that certain TGF-β1 SNPs may be protective against 
ESRD as suggested in this study. A study from India (130) had noted that polymorphisms of 
the “low TGF producing” SNPs was associated with ESRD in patients with a wide range of 
CKD aetiologies including glomerulonephritis, diabetes, reflux nephropathy, FSGS and Alport 
syndrome. It is worthy of note that TGF-beta, though believed to be profibrotic also has anti-
inflammatory properties which may be associated with its CKD preventive effect. More 
detailed transcriptomic and proteomic studies may help decipher the processes involved in 
the CKD-protective effect of TGF-β1. On the other hand, HMOX1 polymorphism did not  





show any relationship with CKD in the HIV population compared to the borderline 
association seen in sickle cell patients with nephropathy. The minor allele frequency of the 
APOL1 SNPs continue to differ across regions of Africa, even in contiguous communities. 
While the APOL1 SNPs do not occur in Ethiopia (101), some communities along the west 
coast of Africa may have almost half of the population carrying the APOL1 genetic risk. In 
our study, we documented a high [44.0% for rs60910145 (G1) and 45.3% for rs73885319 
(G1)] minor allele frequency. This was higher than that obtained among the Yoruba of 
Ibadan (131), Nigeria (27.7-40.6%). Our values were also higher than the recorded frequency 
among the Igbo in Enugu (132). The region where this study was undertaken is more 
southerly and nearer the Atlantic coast where the slave trade ports were located. This may 
be responsible for the equally high APOL1 genetic risk among the population of the 
Caribbean and African Americans. We documented a 2.5-fold increased CKD odds among 
the HIV patients due to the presence of the APOL1 risk but this was not as high as that 
recorded in South Africa (113) where an 89-fold increased odds was noted. It is worthy of 
note, however, that the South African study was done among biopsy-proven HIVAN patients 
unlike this study. Albeit, APOL1 remains an important factor in the pathogenesis of CKD in 
sub-Saharan Africa. 
This work was not without limitations. The meta-analysis and cross-sectional studies used to 
document the prevalence of CKD in the global HIV population and the local population 
employed a definition of CKD that did not take into cognizance individuals with eGFR greater 
than 60ml/min/1.73m2 who have persistent proteinuria. The inclusion of individuals with 
persistent proteinuria would have greatly increased the documented CKD prevalence in the 





albumin-creatinine ratio for detecting CKD in the HIV population, even before elevation of 
serum creatinine (reduction of creatinine-based eGFR). It is obvious that early detection of 
CKD is key to prevention of progression to CKD especially in SSA. Another limitation was the 
lack of properly validated serum creatinine-based eGFR equation for the HIV population in 
SSA. It is possible that there may have been some misclassification of CKD status in the 
component study that addressed the question of CKD prevalence in the local HIV 
population. We attempted to circumvent this problem by using three serum creatinine-
based equations for the estimation of GFR. However, this gap in knowledge presents an 
opportunity to investigate the best GFR estimation equation for HIV patients in SSA which 
will help, not just for screening of CKD purposes but for medication dosing in the HIV 
population. 
A major limitation of this work is the lack of histopathological data which would have helped 
decipher the type of HIV-related nephropathy present in the CKD-HIV group. This limitation 
arose because of the lack of facilities for proper histopathologic characterization of renal 
lesions in the country where this work was undertaken. The delineation of individuals with 
HIVAN would have made for more precise statistical analysis regarding the potential of 
urinary TGF-β1 as a biomarker for CKD diagnosis in HIVAN and HIVICK individuals. Again, 
while APOL1 genetic risk lies at the heart of the pathogenesis of HIVAN, it is not known to 
play a role in the pathogenesis of HIVICK (100). If the proportion of our patients with HIVICK 
is relatively high, it may reduce the magnitude of the computed association between CKD 
occurrence and the APOL1 genetic risk.  






Recommendations & future work 
Considering the foregoing, we wish to make the following recommendations: 
1. It has become imperative to incorporate into HIV care programs, systems that are 
able to integrate HIV treatment with continuous screening and treatment of NCDs in 
an integrated care model that is sustainable in SSA. 
2. Early and regular screening for CKD in the HIV population as suggested by available 
guidelines. 
3. APOL1 screening in the HIV population may be instituted to help predict CKD risk if 
proven by well conducted studies to be cost effective. 
4. We need to evolve the most dependable equation for estimating GFR in the HIV 
population of SSA. 
Conclusion  
There is a high CKD prevalence among HIV patients globally with the highest prevalence 
occurring in West Africa. The prevalence of NCDs is high in the relatively young HIV 
population of the Niger-Delta and may be the most important factor predicting CKD among 
HIV-infected adults in this region. The levels of urinary TGF-β1-creatinine ratio reduces as 
CKD becomes more advanced.  Polymorphism of rs1800470 (TGF-β1) may be protective 
against CKD occurrence in the HIV population while there is no association between HMOX1 
and CKD in the HIV population. One of the highest minor allele frequencies for APOL1 G1 
and G2 occurs among the people of Nigeria’s Niger-Delta. 





There is an increased risk of CKD among HIV-positive adults with APOL1 renal risk variants in 
Nigeria’s Niger-Delta region which may be potentiated by the high prevalence of 
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